

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Psychological barriers to the use of opioid analgesics for treating pain in patients with advanced recurrent cancer (BAROC): protocol for a multicentre cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054914
Article Type:	Protocol
Date Submitted by the Author:	26-Jun-2021
Complete List of Authors:	<p>Tsuno, Takehiko; Yokohama City University Medical Center, Department of Pharmacy; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Analytical Chemistry Fujimiya, Tatsuhiro; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Practical Pharmacy Kawaguchi, Takashi; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Practical Pharmacy Yanaizumi, Ryota; Yokohama City University Medical Center, Department of Anesthesiology Kojima, Keiko; Yokohama City University Medical Center, Department of Palliative Medicine Miyasato, Akime; Tokyo Medical University Hospital, Department of Pharmacy Kanakano, Azuma; Tokyo Medical University Hospital, Department of Pharmacy Saeki, Tomoya; Yokohama Minami Kyou Sai Hospital, Department of Pharmacy Mawatari, Hironori; Yokohama Minami Kyou Sai Hospital, Department of Palliative and Supportive Care Igarashi, Takashi; National Cancer Center-Hospital East, Department of Pharmacy Miura, Tomofumi; National Cancer Center-Hospital East, Department of Palliative Medicine Ogura, Hiroyuki; Kameda Medical Center, Department of Pharmacy Kondo, Junichi; Yokohama City University Medical Center, Department of Pharmacy Tanoue, Tadashi; Tokyo Medical University Hospital, Department of Palliative Medicine Hamada, Hiroshi; Tokyo Medical University Hospital, Department of Palliative Medicine Oyama, Yu; Kameda Medical Center, Department of Medical Oncology Kotani, Akira; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Analytical Chemistry Yamaguchi, Takuhiro; Tohoku University Graduate School of Medicine, Division of Biostatistics Hakamata, Hideki; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Analytical Chemistry</p>
Keywords:	Adverse events < THERAPEUTICS, Cancer pain < ONCOLOGY,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Anaesthesia in oncology < ANAESTHETICS

SCHOLARONE™
Manuscripts

1
2
3
4 **Psychological barriers to the use of opioid analgesics for treating pain in patients with**
5
6
7 **advanced recurrent cancer (BAROC): protocol for a multicentre cohort study**
8
9
10

11
12
13 **Authors:**
14

15
16 Takehiko Tsuno ^{1, 13}, Tatsuhiro Fujimiya ², Takashi Kawaguchi ², Ryota Yanaizumi ³,

17
18 Keiko Kojima ⁴, Akime Miyasato ⁵, Kanako Azuma ⁵, Tomoya Saeki ⁶, Hironori Mawatari ⁷,

19
20
21 Takashi Igarashi ⁸, Tomofumi Miura ⁹, Hiroyuki Ogura ¹⁰, Junichi Kondo ¹, Tadashi Tanoue

22
23
24
25 ¹¹, Hiroshi Hamada ¹¹, Yu Oyama ¹², Akira Kotani ¹³, Takuhiro Yamaguchi ¹⁴, Hideki

26
27
28 Hakamata ¹³
29
30

31 **Affiliations:**
32
33

- 34 1. Department of Pharmacy, Yokohama City University Medical center, Yokohama, Japan
35
36
37 2. Department of Practical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy
38
39 and Life Sciences, Tokyo, Japan
40
41
42
43 3. Department of Anesthesiology, Yokohama City University Medical center, Yokohama,
44
45 Japan
46
47
48
49 4. Department of Palliative Medicine, Yokohama City University Medical center, Yokohama,
50
51 Japan
52
53
54
55 5. Department of Pharmacy, Tokyo Medical University Hospital, Tokyo, Japan
56
57
58 6. Department of Pharmacy, Yokohama Minami Kyousai Hospital, Yokohama, Japan.
59
60

- 1
- 2
- 3
- 4 7. Department of Palliative and Supportive Care, Yokohama Minami Kyousai Hospital,
- 5
- 6
- 7 Yokohama, Japan.
- 8
- 9
- 10 8. Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan.
- 11
- 12
- 13 9. Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, Japan
- 14
- 15
- 16 10. Department of Pharmacy, Kameda Medical Center, Chiba, Japan.
- 17
- 18
- 19 11. Department of Palliative Medicine, Tokyo Medical University Hospital, Tokyo, Japan
- 20
- 21
- 22 12. Department of Medical Oncology, Kameda Medical Center, Chiba, Japan
- 23
- 24
- 25 13. Department of Analytical Chemistry, School of Pharmacy, Tokyo University of Pharmacy
- 26
- 27 and Life Sciences, Tokyo, Japan
- 28
- 29
- 30
- 31 14. Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan
- 32
- 33
- 34
- 35
- 36

37 **Corresponding Author:** Takashi Kawaguchi

38
39
40 Mailing Address: Department of Practical Pharmacy, Tokyo University of Pharmacy and Life
41
42
43 Sciences, 1432-1, Horinouchi, Hachioji-city, Tokyo, 192-0392, Japan

44
45
46 Telephone: +81-042-676-1521

47
48
49 E-Mail: tkawa@toyaku.ac.jp

50
51
52
53
54
55 **Key Words:** adverse events; cancer pain; strong opioids; psychological barriers

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Introduction

Opioid analgesics are essential for the treatment of cancer pain. However, patients are sometimes reluctant to use them because of concerns about addiction and dependence. Rapid pain relief following administration of these drugs may help to overcome the psychological barriers to opioid analgesic use. The primary objective of this study is to determine the relationship between psychological resistance to strong opioid analgesic use and speed of pain improvement in patients with advanced recurrent cancer.

Methods and analysis

This is an ongoing, multicentre, observational study. Patients aged 20 years or older with distant metastasis or advanced recurrent cancer who are receiving strong opioid analgesics for cancer pain for the first time are eligible for participation in this study. We are investigating the relationship between psychological barriers at the start of treatment and pain relief during the first week of treatment in patients receiving strong opioids. The participants are being asked to fill out an electronic patient-reported outcome daily during the first week of treatment. The main purpose of this study is to estimate the psychological barriers to opioid use, as assessed using the Japanese version of the Barrier Questionnaire II. The sample size was determined using one-year prediction rather than using statistical methods based on the study design.

Ethics and dissemination

The study protocol was approved by the ethics committee (approval ID B200600091) of Yokohama City University on 24 August 2020. The protocol has been reviewed by the institutional review board at the following study 3 sites. The protocol will also be reviewed at 1 sites. The results will be published in a peer-reviewed journal and will be presented at a relevant meeting.

Trial registration number

UMIN000042443

Strengths and limitations of the study

- This is the first multicentre observational study to evaluate psychological barriers to the use of strong opioids in Japan.
- We are studying the relationship between improvement in pain intensity and changes in psychological barriers over time.
- Adverse events related to opioid analgesic use are being assessed using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) and CTCAE v5.0-Japan Clinical Oncology Group.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- A limitation of this study is its short observation period, which leads to inability to confirm long-term variations in psychological barriers.

For peer review only

INTRODUCTION

In 2017, there were 24.5 million patients with cancer worldwide, 9.6 million of whom died of cancer.[1] The number of patients with cancer increased by 33% from 2007 to 2017. In 2009, there were 775,601 patients with cancer in Japan.[2] Cancer pain is the most concerning symptom of patients with cancer, with approximately 80% of patients with advanced cancer experiencing moderate to severe pain.[3] Japanese studies have examined the number of patients with cancer requiring treatment for pain relief and the percentage of patients with cancer undergoing treatment for pain relief. When patients experiencing pain were surveyed, 32.2% described themselves as ‘experiencing pain’ and ‘taking analgesics’. It was estimated that approximately 250,000 Japanese patients with cancer require opioid analgesic administration for pain management.

Patients with cancer often hesitate to manage their cancer pain using opioid analgesics. Their hesitation-related perceptions include concerns about addiction, gradual loss of effectiveness, and severe side effects; anxiety due to pain predicting disease progression; and the idea that physicians do not like to talk about pain.[4] The Barriers Questionnaire (BQ) quantitatively measures factors related to patients’ hesitation regarding opioid use. This scale was used to evaluate 270 patients with cancer, and it was found that 37%–85% of them were concerned about addiction and believed that good patients do not complain about pain and side effects. It was also found that older individuals, those from low-income households, and those with low levels of education had higher concerns related to medical narcotics.[5] Furthermore, a relationship between the presence of barriers and pain intensity has also been reported.[6] Moreover, patients’ mental anguish is positively correlated with pain, [7] and opioid analgesics may be insufficient for pain management depending on the patients’ mental state.

A review investigating the barriers to cancer pain management related to healthcare professionals, patients, and systems[8] revealed that patient-related barriers included cognitive and emotional barriers and adherence to treatment. Cognitive barriers included underreporting of symptoms to doctors and misunderstandings related to painkillers. Larger barriers were associated with race, sex, and poor adherence to medication.[9] In particular, a meta-analysis showed that Asians have greater barriers to cancer pain progression, tolerance, and lethality than Westerners.[10] A survey conducted across 214 countries by the International Narcotics Control Board revealed that Japanese individuals consumed fewer medical narcotics per million people per day than those from other countries (1,192 vs. 3,027, respectively). Barriers to narcotic use included lack of training and awareness among healthcare professionals, concern regarding dependency, limited financial resources, procurement issues, cultural behaviour, fear of diversion, and international trade control and regulation. A questionnaire survey carried out by the regulatory authorities of various

1
2
3 countries revealed a high percentage of patients (56%) with concerns about dependency in
4 East Asia, which includes Japan. This suggests that the higher the number of reported
5 barriers, the lower the opioid analgesic use.[11]
6
7

8
9 A questionnaire study conducted in Japan found that 28% of patients with advanced and
10 recurrent cancer believe that opioid analgesic use shortens their lifespan and causes
11 addiction.[12] In a national survey of 5,000 people by Morita et al., 27%–38% participants
12 reported that opioids shorten lifespan, while 24%–33% reported that opioids cause
13 addiction.[13] This emphasises the need to sufficiently consider barriers when initiating
14 treatment with opioids in Japanese patients. Despite the presence of barriers, acceptance of
15 opioid use for pain relief is expected to improve through the practice of high-quality palliative
16 care, pain relief following administration of narcotic medication, and improved confidence in
17 drug safety. Consequently, we believe that pain relief immediately after drug administration is
18 an important factor for breaking these barriers. Furthermore, we believe that patients who can
19 confidently use opioid analgesics will take a shorter time to achieve the optimal dose and will
20 achieve immediate pain relief. Patients' pain and mental state fluctuate daily and diurnally,
21 and comparing findings before and after an intervention may lead to inaccurate results. A
22 detailed assessment of the speed of pain relief requires repeated evaluation over time. To date,
23 few reports have investigated the relationship between the presence of psychological
24 resistance to the use of strong opioid analgesics and the speed of pain relief in patients with
25 advanced recurrent cancer. Therefore, we designed this study to address the need for
26 sufficient verification of the relationship between psychological barriers and the speed of pain
27 relief.
28
29
30
31
32
33
34
35
36
37
38

39 The purpose of this study is to elucidate the relationship between psychological barriers to
40 the use of strong opioid analgesics and the speed of pain relief in patients with advanced
41 recurrent cancer. If it is found that cancer pain relief is difficult to achieve in patients who are
42 hesitant to use strong opioid analgesics, this study may provide important information on how
43 to assuage their reluctance and bring about rapid pain improvement.
44
45
46
47

48 **METHODS AND ANALYSIS**

49 **Study design**

50
51 This is an ongoing, multicentre, longitudinal, observational study. We are investigating the
52 relationship between psychological barriers at the start of treatment and pain relief during the
53 first week of treatment in patients receiving strong opioids for cancer pain. We are also
54 evaluating the relationship between psychological barriers and adverse events associated with
55 the use of strong opioids. Patients were not invited to collaborate during the study design;
56 therefore, this study protocol was developed without patient and public involvement.
57
58
59
60

Study setting, participants, and recruitment

Recruiting is being performed at seven sites in Japan. The inclusion and exclusion criteria are shown in Box 1. The main inclusion criterion is patients aged 20 years or older with distant metastasis or advanced recurrent cancer who receive first treatment with strong opioid analgesics for cancer pain. The main exclusion criteria are patients with difficulties in providing electronic patient-reported outcome (ePRO) data and patients with neuropathic pain. Eligible patients are being invited to participate in the study by investigators at each study site. These patients are being asked to complete an ePRO daily during the first week of treatment. Observation is being discontinued if any of the following occurs: (1) death during observation, (2) the patient's condition deteriorates and the healthcare professional determines that the intervention cannot be continued; (3) the patient withdraws consent; and (4) the investigators judge that observation cannot be continued for any other reason. As a rule, standard pain relief treatments are being provided at each facility. We are neither restricting the provision of combination or supportive treatment nor specifying the post-treatment.

Outcome measures

Table 1 shows the timeline of enrolment and assessment. We are using the Japanese version of the Barrier Questionnaire-II (JBQ-II) [13, 14] to assess psychological barriers to opioid analgesic use and the Decision Regret Scale (DRS) [15, 16] to evaluate regret related to decision making. We are using the Patient-Reported Outcomes (PRO-) version of the Common Terminology Criteria for Adverse Events (CTCAE) [19, 20] and the CTCAE v5.0 to assess adverse events. We are evaluating pain severity using the Brief Pain Inventory (BPI)-Short Form (SF) [21-23] and Personalised Pain Goal (PPG) [25].

Japanese version of the Barrier Questionnaire II

To reflect practical changes in pain management, the BQ, which is a measure of psychological barriers, was revised to create the Barrier Questionnaire II (BQ-II).[14] The JBQ-II is the Japanese version of the BQ-II. It has been validated (Cronbach's $\alpha = 0.92$). [15] The JBQ-II comprises of the following five subscales: barriers related to psychological effects (distrust of symptomatic treatment), barriers related to fatalism (fateful resignation), barriers related to communication (loss of intention), barriers related to adverse effects (fear of side effects), and barriers related to disease progression (escape/defence from illness). Each item is graded on a six-point Likert scale (0–5). The subscale and total scores (overall barrier) are calculated as the mean of the scores (0–5) for the relevant items, with higher numbers indicating higher barriers.

Patient Global Impression of Severity

Currently, the cut-off values for classifying the presence and magnitude of psychological

1
2
3 barriers are unknown. In this study, we are using the Patient Global Impression of Severity
4 (PGIS) to classify the participants' JBQ-II scores. The PGIS has not been validated to classify
5 psychological barriers. We are grading responses to the item 'At present, how reluctant are
6 you to use opioids for pain relief?' using following seven-point scale: 0, not at all; 1, not
7 reluctant; 2, almost not reluctant; 3, neither; 4, slightly reluctant; 5, reluctant; and 6,
8 extremely reluctant.
9
10
11
12

13 **Decision Regret Scale**

14
15 Regret is a negative emotion felt when one realises or imagines that one has made the wrong
16 choice. It is a retrospective, unpleasant feeling, and people tend to focus on 'what is good'
17 rather than 'what is bad'. It has been reported to be associated with negative emotions such as
18 disappointment and to involve some aspect of self-blame.[16] We are evaluating regret using
19 the DRS, which measures patient conflict regarding decision making during the treatment
20 process.[17] A Japanese version of the DRS has been developed and validated (Cronbach's α
21 = 0.85).[18] It consists of five items, and the total score ranges from 0 to 100, with higher
22 scores indicating greater regret.
23
24
25
26
27
28

29 **Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse** 30 **Events**

31
32 The National Cancer Institute (NCI)-CTCAE is a standardised tool for assessing adverse
33 events during cancer treatment. However, since grading is based on the clinician's judgement,
34 it may not be possible to accurately evaluate the patient's condition, especially when
35 subjective aspects are involved.[19] Basch et al. reported a discrepancy between clinicians'
36 and the patients' assessments, indicating that clinicians underestimate CTCAE grades.[20]
37 Therefore, the NCI has developed the PRO-CTCAE, which incorporates the concept of PRO
38 into the CTCAE.[21] Its Japanese version has been validated.[22] In this study, we are
39 evaluating the participants' main symptoms, such as pain, and characteristic adverse events
40 related to opioid analgesic use, such as nausea/vomiting, constipation, drowsiness, fatigue,
41 and thirst. We are also evaluating an additional item to measure the psychological burden of
42 using opioid analgesics.
43
44
45
46
47
48
49

50 **Brief Pain Inventory-Short Form**

51
52 The effect of pain on daily life differs from pain intensity. It is related to the amount of pain
53 that results in hinderance of activities such as walking, bathing, and sleeping. The BPI is a
54 standardised scale that has been confirmed to be reliable and valid for assessing pain intensity
55 and its effect on daily life.[23] It is a 15-item questionnaire that evaluates pain. Each item is
56 graded on an 11-point scale, with scores ranging from 0 to 10. The Japanese version of this
57 scale has already been validated, and its reliability and usefulness have been established
58 (Cronbach's α = 0.80).[24] To decrease the burden on patients related to the number of
59
60

1
2
3 questions to be answered, we are only using the ‘worst pain in the last 24 hours’ item of the
4 BPI-SF, based on a report by Atkinson et al.[25]
5
6
7

8 **Personalised Pain Goal**

9 As an index of pain, the numerical rating scale (NRS) is generally used to assess the average
10 pain over 24 hours and the degree of disability in daily life due to pain (disturbance of life)
11 using an 11-point scale, with scores ranging from 0 (none) to 10 (the worst possible). A score
12 of four or higher indicates moderate pain/disability, while a score of seven or higher indicates
13 severe pain/disability.[26] From the perspective of personalised medicine for the treatment of
14 cancer pain, it is important to involve the patient in treatment goal setting and to provide
15 treatment with the aim of achieving those goals. In recent years, the PPG has been used as an
16 outcome measure to determine pain-relief goals in non-Japanese patients with cancer.[27] The
17 PPG helps patients set a personalised pain-relief goal using the following question: ‘At what
18 level would you feel comfortable with pain?’ In our study, patients are being asked to use the
19 NRS to indicate their pain treatment goals. Pain treatment is considered to be successful
20 (achievement of the PPG) if the patient's NRS score for pain at the time of assessment is
21 below the PPG.
22
23
24
25
26
27
28
29

30 **Others**

31 Since strong opioid use during the study period might affect the time to achieve the PPG, the
32 following items are being investigated: (1) whether any dose of the base strong opioid was
33 missed, (2) presence of increased opioid dosage, (3) presence of opioid switching, and (4) use
34 of strong opioids before starting base medication with or without rescue medication.
35
36
37
38

39 **Sample size**

40 The sample size was determined to be 200 based on the number of new patients being
41 prescribed opioids per year at the study sites, taking into account the eligibility criteria. The
42 sample size was not calculated using statistical methods.
43
44
45
46

47 **Data collection and timeline**

48 We are using the electronic data capture (EDC) systems, Viedoc 4, and ePRO, ViedocMe
49 (Viedoc Technologies, Sweden), to enrol the participants and collect their data. During
50 enrolment, the investigators are inputting their personal accounts and passwords into the
51 system. Investigators at each site are using the EDC system to input data into an electronic
52 case report form. Patients are being administered the PROs using an ePRO application on
53 their device (smartphone, tablet, or personal computer) at eight time points: at baseline and on
54 days one to seven. The patients may register their phone number or email address in the EDC
55 system and use the ePRO reminder function. The investigators are providing the patients with
56 details about the trial. After obtaining patient consent, data regarding each patient's
57
58
59
60

1
2
3 psychosocial background; JBQ-II, PRO-CTCAE, and BPI-SF scores; and PPG are being
4 collected from their electronic device. Data regarding demographics, medical history, and
5 CTCAE v5.0-Japan Clinical Oncology Group (JCOG) score are being collected, entered into
6 the web-based EDC system at the study site, and linked to the baseline PRO data. After
7 starting to receive opioids, each patient is being asked to record their BPI-SF (worst pain in
8 the last 24 hours) score daily for seven days. On the last day, each patient is being
9 administered the JBQ-II, PGIS, DRS, and PRO-CTCAE. Each patient's CTCAE v5.0-JCOG
10 data is being collected by an investigator at the time of their next visit (days 8–15). In
11 addition, we are recording each patient's use of strong opioid medication prior to starting base
12 medication and whether any dose of the strong base opioid has been missed. The study
13 timeline is presented in Table 1.
14
15
16
17
18
19
20

21 **Data monitoring**

22 The data centre is located at the Department of Practical Pharmacy, School of Pharmacy,
23 Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan. No personally identifiable
24 information is being entered into the EDC system, and the participating sites are not
25 communicating personal information to the data centre. Since this study involves data
26 collection using an EDC system, the data is being stored on the server during the study period.
27 After the end of the study period, the data exported from the EDC system will be stored at the
28 data centre until the main presentation or publication. Following this, the data will be stored at
29 the research secretariat and data centre. Monitoring is being performed to ensure that the
30 study is conducted according to the protocol and that the data is collected accurately. Central
31 monitoring is being performed by the data centre based on the EDC data collected. The data
32 centre has been submitting monthly monitoring reports to the researchers, is sharing
33 information with the researchers at all the study sites, and is striving for improvement. There
34 is no data monitoring committee, and auditing has not been planned for this study.
35
36
37
38
39
40
41
42
43

44 **Harm**

45 This is a non-intervention observational study with low invasiveness. We expect no serious
46 harm to occur. However, the contents of the questionnaire may cause mental strain to the
47 participants. Consent may be withdrawn even while filling the questionnaire, and the
48 participants are being sufficiently explained about the study prior to enrolment.
49
50
51
52

53 **Statistical analysis**

54 The primary outcome is the JBQ-II score at baseline. The mean JBQ-II score at baseline
55 will be calculated for all patients, and its 95% confidence interval will be estimated.
56 Secondary, the relationships between the total JBQ-II score and the PPG achievement period,
57 baseline and visit 2 JBQ-II scores, changes in JBQ-II scores, and PPG achievement rate on
58 day seven will be examined. Patients will be grouped based on their PGIS scores, and the
59
60

1
2
3 difference between the DRS score and PPG achievement rate between the two groups will be
4 estimated and tested. The relationship between the JBQ-II and trends in pain scores will be
5 investigated. In addition, the proportion of adverse events will be calculated using the
6 PRO-CTCAE and CTCAE v5.0-JCOG for safety analysis.
7
8
9

10 **ETHICS AND DISSEMINATION**

11 **Research ethical approval**

12 The study is being performed in accordance with the Declaration of Helsinki; Ethical
13 Guidelines for Medical and Health Research Involving Human Subjects published by the
14 Japanese Ministry of Education, Science and Technology and the Ministry of Health, Labour,
15 and Welfare; and the modified Act on the Protection of Personal Information. The protocol
16 was approved by the ethics committee (approval ID B200600091) of Yokohama City
17 University on 24 August 2020. The protocol version was 1.1 in November 2020. The protocol
18 has been reviewed by the institutional review board at the following study sites: Tokyo
19 Medical University Hospital, Yokohama Minami Kyou Sai Hospital, and National Cancer
20 Center Hospital East. The protocol will also be reviewed at the Kameda General Hospital.
21
22
23
24
25
26
27
28

29 **Consent**

30 Before enrolment, an investigator explains the details of the study to the patients and gives
31 them time to think about it. All participants are being informed of their right to withdraw their
32 consent without prejudice. The study is being conducted after obtaining written consent from
33 all the patients.
34
35
36
37

38 **Trial registration**

39 This trial has been registered at the University Hospital Medical Information Network
40 Clinical Trials Registry (UMIN000042443).
41
42
43

44 **Access to data**

45 Investigators are only able to access the case data collected at their respective study sites.
46 Only clinical data managers at the data centre have access to reported case data through the
47 EDC system during the study period.
48
49
50

51 **Dissemination policy**

52 The results of this study will be presented at conferences and published in national and
53 international peer-reviewed medical journals.
54
55
56

57 **DISCUSSION**

58 To date, most studies on psychological barriers to analgesia have not specifically studied the
59 use of strong opioid analgesics. The BAROC is an exploratory study that investigates the
60

1
2
3 relationship between psychological barriers and improvement in pain. It is important to use
4 PROs, as pain improvement contributes to health-related quality of life. Psychological
5 barriers may be influenced by opioid switching and analgesic use before starting to regularly
6 use strong opioid analgesics. These data are also being collected using the EDC system.
7
8
9

10
11 The BAROC is the first multicentre study in Japan to evaluate the relationship between
12 psychological barriers and cancer pain. The study sites include university hospitals,
13 specialised cancer hospitals, and community hospitals, and it is expected that the enrolled
14 patients will have diverse demographics. One of the characteristics of this study is that
15 eligibility is not being limited by performance status. This means that patients with poor
16 performance status may be eligible to participate in this study. Patients being administered
17 strong opioid analgesics often have a poor performance status, and our data will reflect actual
18 clinical practice.
19
20
21
22
23

24
25 Although the use of strong opioid analgesics can be beneficial in the treatment of cancer
26 pain, it can also cause adverse events. Nausea and drowsiness commonly occur during opioid
27 induction. There is concern that these symptoms may lead to decreased adherence and,
28 therefore, interruption of pain treatment. In addition, the occurrence of adverse events can
29 cause anxiety, worry, and other psychological burdens, amplifying resistance to opioid
30 analgesic use. In this study, data on adverse event occurrence is being collected not only from
31 physicians, but also from the patients themselves using the PRO-CTCAE. Because adverse
32 events and psychological barriers are closely related, precision in adverse event assessment is
33 required. Thus, it is important to use the PRO-CTCAE in addition to the CTCAE in order to
34 consider the relationship between psychological barriers and adverse events and to enable
35 high-quality adverse event assessment.
36
37
38
39
40
41

42
43 This study protocol has several limitations. First, this is a hypothetical, moulded
44 observational study. The number of subjects was not determined using statistical methods and
45 was based on the caseload of the participating institutions. Second, because this is an
46 observational study, we are neither specifying the explanation to be provided to the patients
47 before initiation of strong opioid analgesic use, nor are we specifying the setting in which this
48 explanation is to be provided; each facility is following their own protocol in this regard.
49 Psychological barriers may fluctuate depending on the method of explanation and the
50 environment at that time. Third, we are excluding patients with cognitive impairment or
51 mental illness and those who cannot operate a smartphone or tablet from participation in the
52 study. Therefore, we will not be able to enrol all the patients receiving strong opioid
53 analgesics. Most of the excluded participants are likely to be older adults. Finally, due to the
54 coronavirus disease-2019 pandemic, it may be difficult to recruit patients due to restrictions
55
56
57
58
59
60

1
2
3 on hospital functions and patients' reluctance to receive care. As a result, enrolment for this
4 study may need to be delayed.
5
6

7
8 The BAROC study may provide important information that may help to reduce
9 psychological barriers to cancer pain relief in patients who are reluctant to use strong opioid
10 analgesics. Clarifying the relationship between the achievement of pain relief goals and
11 psychological barriers at the time of introduction of strong opioid analgesics will provide
12 basic data for future interventional studies and contribute to improving the quality of cancer
13 pain treatment.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Acknowledgements

We are grateful to Mashiko T and Miyaji T for their long-term collaboration and advice. The authors thank in advance all the patients, investigators, and institutions involved in this study. We also thank Editage (www.editage.com) for providing writing support.

Contributors

TT contributed to trial conception and is the principal investigator.

TT, TF, TK, AK, and HH contributed to the study design.

TF, TK, and TY contributed to data management. TK and TY planned the data analysis.

Data analysis and interpretation will be conducted by TT, TF, TK, and TY.

TT, AM, KA, TS, TI, and JK acquired the data.

All authors have read and approved the final manuscript and meet the criteria for authorship as established by the International Committee of Medical Journals Editors.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing interests

None declared.

Patient and public involvement

Patients and/or the public were not involved in planning the design, conduct, reporting, or dissemination of this research.

Patient consent for publication

Not required.

Provenance and peer review

Not commissioned; externally peer reviewed.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Takehiko Tsuno <https://orcid.org/0000-0002-5844-1226>

Tatsuhiko Fujimiya <https://orcid.org/0000-0001-8198-7465>

Takashi Kawaguchi <https://orcid.org/0000-0003-2446-7716>

For peer review only

REFERENCES

1. Fitzmaurice, C., et al., *Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study*. JAMA Oncol, 2018. **4**(11): p. 1553-1568.
2. Hori, M., et al., *Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project*. Jpn J Clin Oncol, 2015. **45**(9): p. 884-91.
3. Bruera, E. and H.N. Kim, *Cancer pain*. JAMA, 2003. **290**(18): p. 2476-9.
4. Jacobsen, R., et al., *Patient-related barriers to cancer pain management: a systematic exploratory review*. Scand J Caring Sci, 2009. **23**(1): p. 190-208.
5. Ward, S.E., et al., *Patient-related barriers to management of cancer pain*. Pain, 1993. **52**(3): p. 319-24.
6. Al-Atiyyat, N.M.H. and A.H. Vallerand, *Patient-related attitudinal barriers to cancer pain management among adult Jordanian patients*. Eur J Oncol Nurs, 2018. **33**: p. 56-61.
7. Ell, K., et al., *Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer*. J Clin Oncol, 2005. **23**(13): p. 3052-60.
8. Kwon, J.H., *Overcoming barriers in cancer pain management*. J Clin Oncol, 2014. **32**(16): p. 1727-33.
9. Nguyen, L.M., et al., *Frequency and predictors of patient deviation from prescribed opioids and barriers to opioid pain management in patients with advanced cancer*. J Pain Symptom Manage, 2013. **45**(3): p. 506-16.
10. Chen, C.H. and S.T. Tang, *Meta-analysis of cultural differences in Western and Asian patient-perceived barriers to managing cancer pain*. Palliat Med, 2012. **26**(3): p. 206-21.
11. Berterame, S., et al., *Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study*. Lancet, 2016. **387**(10028): p. 1644-56.
12. Akiyama, M., et al., *Knowledge, beliefs, and concerns about opioids, palliative care, and homecare of advanced cancer patients: a nationwide survey in Japan*. Support Care Cancer, 2012. **20**(5): p. 923-31.
13. Morita, T., et al., *Knowledge and beliefs about end-of-life care and the effects of specialized palliative care: a population-based survey in Japan*. J Pain Symptom Manage, 2006. **31**(4): p. 306-16.
14. Gunnarsdottir, S., et al., *Patient-related barriers to pain management: the Barriers Questionnaire II (BQ-II)*. Pain, 2002. **99**(3): p. 385-96.
15. Sakakibara, N., et al., *Validation of the Japanese version of the barriers questionnaire II in cancer pain management: a cross-sectional study*. BMC Palliat Care, 2020. **19**(1): p. 102.
16. Zeelenberg M, P.R., *A theory of regret regulation 1.0*. Journal of Consumer Psychology, 2007. **17**: p. 3-18.
17. Brehaut, J.C., et al., *Validation of a decision regret scale*. Med Decis Making, 2003. **23**(4): p. 281-92.
18. Tanno, K., et al., *Validation of a Japanese Version of the Decision Regret Scale*. J Nurs Meas, 2016. **24**(1): p. E44-54.
19. Basch, E., *The missing voice of patients in drug-safety reporting*. N Engl J Med, 2010. **362**(10): p. 865-9.
20. Basch, E., et al., *Patient versus clinician symptom reporting using the National Cancer Institute*

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.* Lancet Oncol, 2006. **7**(11): p. 903-9.
21. Basch, E., et al., *Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.* J Clin Oncol, 2018: p. JCO2018788620.
22. Kawaguchi, T., et al., *The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events.* J Patient Rep Outcomes, 2017. **2**(1): p. 2.
23. Cleeland, C.S. and K.M. Ryan, *Pain assessment: global use of the Brief Pain Inventory.* Ann Acad Med Singapore, 1994. **23**(2): p. 129-38.
24. Uki, J., et al., *A brief cancer pain assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory--BPI-J.* J Pain Symptom Manage, 1998. **16**(6): p. 364-73.
25. Atkinson, T.M., et al., *The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations.* Pain Med, 2010. **11**(3): p. 337-46.
26. Serlin, R.C., et al., *When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function.* Pain, 1995. **61**(2): p. 277-284.
27. Dalal, S., et al., *Achievement of personalized pain goal in cancer patients referred to a supportive care clinic at a comprehensive cancer center.* Cancer, 2012. **118**(15): p. 3869-77.

Box 1: Eligibility criteria**Inclusion criteria**

1. Patients diagnosed with remote metastasis or advanced recurrent cancer by a doctor
2. First treatment with strong opioid analgesics for cancer pain
3. Patients who are 20 years or older
4. Highest intensity of pain in the last 24 hours of NRS 4 or higher
5. Patients providing written consent for participating in the study

Exclusion criteria

1. Patients who have difficulty in providing ePRO data (e.g. those who do not have a smartphone or cannot use a tablet)
2. Patients with cognitive impairments that would hinder PRO administration
3. Patients with mental illnesses that would hinder PRO administration
4. Patients whose main mechanism of pain is neuropathic
5. Other factors that the attending physician deems inappropriate

ePRO, electronic version of the Patient-Reported Outcomes Questionnaire; NRS, numerical rating scale; PRO, Patient-Reported Outcomes Questionnaire.

Table 1: Study timeline

Day	Visit 1	Time after initiating opioid therapy							Visit 2
	0 (baseline)	1	2	3	4	5	6	7	8–15
Patient reported outcomes :									
Psychosocial background	•								
JBQ-II	•							•	
PGIS								•	
DRS								•	
PRO-CTCAE	•							•	
BPI-SF (strongest pain in the last 24 hours)	•	•	•	•	•	•	•	•	
PPG	•								
Use of strong opioids before starting base medication with or without rescue medication (outpatients)		•							
Whether any dose of the base strong opioid was missed (outpatients)								•	
Clinician reported outcomes:									
Demographics and medical history	•								
CTCAE v5.0-JCOG	•								•
Presence of increased opioid dosage									•
Presence of opioid switching									•
Use of strong opioids before starting base medication with or without rescue medication (inpatients)									•
Whether any dose of the base strong opioid was missed (inpatients)									•

BPI-SF, Brief Pain Inventory-Short Form; CTCAE, Common Terminology Criteria for Adverse Events; DRS, Decision Regret Scale; JBQ-II, Japanese version of the Barrier Questionnaire II; JCOG, Japan Clinical Oncology Group; PGIS, Patient Global Impression of Severity; PPG, Personalised Pain

1
2
3 Goal; PRO, Patient Reported Outcome
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

Psychological barriers to the use of opioid analgesics for treating pain in patients with advanced recurrent cancer (BAROC): protocol for a multicentre cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054914.R1
Article Type:	Protocol
Date Submitted by the Author:	12-Jan-2022
Complete List of Authors:	<p>Tsuno, Takehiko; Yokohama City University Medical Center, Department of Pharmacy; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Analytical Chemistry Fujimiya, Tatsuhiro; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Practical Pharmacy Kawaguchi, Takashi; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Practical Pharmacy Yanaizumi, Ryota; Yokohama City University Medical Center, Department of Anesthesiology Kojima, Keiko; Yokohama City University Medical Center, Department of Palliative Medicine Miyasato, Akime; Tokyo Medical University Hospital, Department of Pharmacy Kanao, Azuma; Tokyo Medical University Hospital, Department of Pharmacy Saeki, Tomoya; Yokohama Minami Kyou Sai Hospital, Department of Pharmacy Mawatari, Hironori; Yokohama Minami Kyou Sai Hospital, Department of Palliative and Supportive Care Igarashi, Takashi; National Cancer Center-Hospital East, Department of Pharmacy Miura, Tomofumi; National Cancer Center-Hospital East, Department of Palliative Medicine Ogura, Hiroyuki; Kameda Medical Center, Department of Pharmacy Kondo, Junichi; Yokohama City University Medical Center, Department of Pharmacy Tanoue, Tadashi; Tokyo Medical University Hospital, Department of Palliative Medicine Hamada, Hiroshi; Tokyo Medical University Hospital, Department of Palliative Medicine Oyama, Yu; Kameda Medical Center, Department of Medical Oncology Kotani, Akira; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Analytical Chemistry Yamaguchi, Takuhiro; Tohoku University Graduate School of Medicine, Division of Biostatistics Hakamata, Hideki; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Analytical Chemistry</p>
Primary Subject	Palliative care

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Heading	
Secondary Subject Heading:	Anaesthesia, Oncology, Patient-centred medicine, Pharmacology and therapeutics
Keywords:	Adverse events < THERAPEUTICS, Cancer pain < ONCOLOGY, Anaesthesia in oncology < ANAESTHETICS

SCHOLARONE™
Manuscripts

1
2
3
4 1 **Psychological barriers to the use of opioid analgesics for treating pain in patients with**
5
6
7 2 **advanced recurrent cancer (BAROC): protocol for a multicentre cohort study**
8
9

10
11 3 **Authors:**
12

13 4 Takehiko Tsuno ^{1, 13}, Tatsuhiro Fujimiya ², Takashi Kawaguchi ², Ryota Yanaizumi ³, Keiko
14 5 Kojima ⁴, Akime Miyasato ⁵, Kanako Azuma ⁵, Tomoya Saeki ⁶, Hironori Mawatari ⁷,
15 6 Takashi Igarashi ⁸, Tomofumi Miura ⁹, Hiroyuki Ogura ¹⁰, Junichi Kondo ¹, Tadashi Tanoue
16 7 ¹¹, Hiroshi Hamada ¹¹, Yu Oyama ¹², Akira Kotani ¹³, Takuhiro Yamaguchi ¹⁴, Hideki
17 8 Hakamata ¹³
18
19
20
21

22 9 **Affiliations:**
23

- 24 10 1. Department of Pharmacy, Yokohama City University Medical Center, Yokohama, Japan
25
26 11 2. Department of Practical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and
27 12 Life Sciences, Tokyo, Japan
28
29 13 3. Department of Anesthesiology, Yokohama City University Medical Center, Yokohama,
30 14 Japan
31
32 15 4. Department of Palliative Medicine, Yokohama City University Medical Center, Yokohama,
33 16 Japan
34
35 17 5. Department of Pharmacy, Tokyo Medical University Hospital, Tokyo, Japan
36
37 18 6. Department of Pharmacy, Yokohama Minami Kyou Sai Hospital, Yokohama, Japan.
38
39 19 7. Department of Palliative and Supportive Care, Yokohama Minami Kyou Sai Hospital,
40 20 Yokohama, Japan.
41
42 21 8. Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan.
43
44 22 9. Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, Japan
45
46 23 10. Department of Pharmacy, Kameda Medical Center, Chiba, Japan.
47
48 24 11. Department of Palliative Medicine, Tokyo Medical University Hospital, Tokyo, Japan
49
50 25 12. Department of Medical Oncology, Kameda Medical Center, Chiba, Japan
51
52
53
54
55
56
57
58
59
60

1
2
3 1 13. Department of Analytical Chemistry, School of Pharmacy, Tokyo University of Pharmacy
4 and Life Sciences, Tokyo, Japan
5 2

6
7 3 14. Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan
8
9 4

10
11
12
13 5 **Corresponding Author:**

14 6 Takashi Kawaguchi

15 7 Department of Practical Pharmacy,

16 8 Tokyo University of Pharmacy and Life Sciences,

17 9 1432-1, Horinouchi, Hachioji-city, Tokyo, 192-0392, Japan.

18 10 Telephone: +81-042-676-1521

19 11 E-Mail: tkawa@toyaku.ac.jp
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

12
13 **Word count:** 3988

14 **Key Words:** adverse events; cancer pain; strong opioids; psychological barriers

1 **ABSTRACT**

2 **Introduction**

3 Opioid analgesics are essential for treating cancer pain. However, patients are sometimes
4 reluctant to use them because of concerns about addiction and dependence. Rapid pain relief
5 following opioid administration may help overcome the psychological barriers to opioid
6 analgesic use. This study aims to determine the relationship between psychological resistance
7 to strong opioid analgesic use and pain amelioration speed in patients with advanced recurrent
8 cancer.

9 **Methods and analysis**

10 This ongoing, multicentre, observational study enrolls patients aged 20 years or older with
11 distant metastasis or advanced recurrent cancer receiving strong opioid analgesics for cancer
12 pain for the first time. We are investigating the relationship between psychological barriers at
13 the start of treatment and pain relief during the first week of treatment in these patients. The
14 primary outcome is the Japanese version of the Barriers Questionnaire-II score at baseline. The
15 secondary outcomes are the relationships between psychological barriers to strong opioid
16 analgesic use and changes in pain over time. The participants are asked to fill out an electronic
17 patient-reported outcome daily during the first week of treatment. The sample size was
18 determined based on the number of patients in the year prior to study commencement who used

1
2
3
4 1 strong opioid analgesics, met the eligibility criteria, and could be expected to consent to
5
6
7 2 participate in the study.
8
9

10 11 3 **Ethics and dissemination** 12 13 14

15 4 The study protocol was approved by the ethics committee (approval ID B200600091) of
16
17
18 5 Yokohama City University on 24 August 2020. The protocol has been reviewed by the
19
20
21 6 institutional review boards at the four participating study sites. The results will be published in
22
23
24 7 a peer-reviewed journal and will be presented at a relevant meeting.
25
26
27

28 8 **Trial registration number** 29 30 31

32 9 UMIN000042443
33
34
35
36
37 10
38
39
40

41 11 **Strengths and limitations of the study** 42 43 44

- 45 12 ➤ This is the first multicentre observational study to evaluate psychological barriers to the
46
47
48 13 use of strong opioids in Japan.
49
50
51 14 ➤ An understanding of Japanese version of the Barriers Questionnaire-II scores before and
52
53
54 15 after opioid initiation may be useful for educating healthcare providers to reduce
55
56
57 16 psychological barriers.
58
59
60 17 ➤ Adverse events related to opioid analgesic use are assessed using the Patient-Reported

1
2
3
4 1 Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-
5
6
7 2 CTCAE) and CTCAE v5.0-Japan Clinical Oncology Group.
8
9

10 3 ➤ A limitation of this study is its short observation period, which leads to an inability to
11
12
13 4 confirm long-term variations in psychological barriers.
14
15
16
17 5

For peer review only

1 INTRODUCTION

2 In 2017, there were 24.5 million incident cancer cases worldwide, 9.6 million of whom died of
3 cancer. [1] The incidence of cancer increased by 33% from 2007 to 2017. In 2009, there were
4 775,601 patients with cancer in Japan. [2] Cancer pain is the most concerning symptom of
5 patients with cancer, with approximately 80% of patients with advanced cancer experiencing
6 moderate to severe pain. [3] Japanese studies have examined the percentage of patients with
7 cancer requiring and undergoing treatment for pain relief. In a survey, 60% of patients with
8 cancer had pain, with 20% having moderate to severe pain. [4] Based on the prevalence of
9 cancer in Japan, it is estimated that approximately 155,000 Japanese patients have moderate to
10 severe pain and require opioid analgesics.

11 Patients with cancer often hesitate to manage their cancer pain using opioid analgesics. Their
12 hesitation-related perceptions include concerns about addiction, gradual loss of effectiveness,
13 severe side effects, anxiety due to pain predicting disease progression, and the idea that
14 physicians are reluctant to talk about pain. [5] The Barriers Questionnaire (BQ) quantitatively
15 measures factors related to patients' hesitation regarding opioid use. This scale was used to
16 evaluate 270 patients with cancer, and it was found that 37%–85% of them were concerned
17 about addiction and believed that good patients do not complain about pain and side effects.
18 Additionally, older individuals, those from low-income households, and those with low levels

1
2
3
4 1 of education had higher concerns related to medical narcotics. [6] Furthermore, a relationship
5
6
7 2 between the presence of barriers and pain intensity has also been reported. [7] Moreover,
8
9
10 3 patients' mental anguish is positively correlated with pain, [8] and opioid analgesics may be
11
12
13 4 insufficient for pain management depending on the patients' mental state.

14
15
16
17 5 A review investigating the barriers to cancer pain management related to healthcare
18
19
20 6 professionals, patients, and systems [9] revealed that patient-related barriers included cognitive
21
22
23 7 and emotional barriers and treatment adherence. Cognitive barriers included underreporting of
24
25
26 8 symptoms to doctors and painkiller-related misunderstandings. Large barriers were associated
27
28
29 9 with race, sex, and poor medication adherence. [10] In particular, a meta-analysis showed that
30
31
32 10 Asians have greater barriers to cancer pain progression, tolerance, and lethality than Westerners.
33
34
35 11 [11] A survey conducted across 214 countries by the International Narcotics Control Board
36
37
38 12 revealed that Japanese individuals consumed fewer medical narcotics per million people per
39
40
41 13 day than those from other countries (1,192 vs 3,027, respectively). Barriers to narcotic use
42
43
44 14 included lack of training and awareness among healthcare professionals, concern regarding
45
46
47 15 dependency, limited financial resources, procurement issues, cultural behaviour, fear of
48
49
50 16 diversion, and international trade control and regulation. [12] Using a questionnaire, regulatory
51
52
53 17 authorities of various countries found a high percentage of patients (56%) with concerns about
54
55
56 18 dependency in East Asia, which includes Japan. This suggests that the higher the number of
57
58
59 19 reported barriers, the lower the opioid analgesic use. [12]

1
2
3
4 1 A Japanese questionnaire study found that 28% of patients with advanced and recurrent cancer
5
6
7 2 believe that opioid analgesic use shortens their lifespan and causes addiction. [13] A national
8
9
10 3 survey of 5,000 people revealed that 27%–38% of participants reported that opioids shorten
11
12
13 4 lifespan, while 24%–33% reported that opioids cause addiction. [14] This emphasises the need
14
15
16 5 to thoroughly consider barriers when initiating treatment with opioids in Japanese patients.
17
18
19 6 Despite barriers, acceptance of opioid use for pain relief is expected to improve through the
20
21
22 7 practice of high-quality palliative care, pain relief following administration of narcotic
23
24
25 8 medication, and improved confidence in drug safety. [14] Consequently, we believe that pain
26
27
28 9 relief immediately after drug administration is important for breaking these barriers and that
29
30
31 10 patients who confidently use opioid analgesics will quickly achieve the optimal dose and
32
33
34 11 experience immediate pain relief. Patients' pain and mental state fluctuate daily and diurnally,
35
36
37 12 and comparing pre- and post-intervention findings may lead to inaccurate results. [8] A detailed
38
39
40 13 assessment of the speed of pain relief requires repeated evaluation over time.

41
42
43
44 14 Several studies have shown a positive correlation between psychological barriers and pain level,
45
46
47 15 possibly due to inadequate analgesic use. [7 15] Furthermore, psychological barriers were lower
48
49
50 16 when analgesics appropriate for the level of pain were used than when inadequate analgesics
51
52
53 17 were used. However, the use of strong opioid analgesics has not been specifically studied. [16-
54
55
56 18 18] A study conducted at six medical centres in three countries that regulate the use of strong
57
58
59 19 opioid analgesics examined psychological barriers in patients who had been using strong opioid
60

1
2
3
4 1 analgesics for more than 72 hours and showed that patients who had been using strong opioid
5
6
7 2 analgesics for a short period reported higher barrier scores than those who had been using them
8
9
10 3 for a long time. [19] Therefore, it is important for future cancer pain treatment to identify
11
12
13 4 changes in psychological barriers during and after initiation of use of strong opioid analgesics.
14
15
16 5 However, these are cross-sectional studies, and, to date, only a few studies have investigated
17
18
19 6 the relationship between psychological resistance to strong opioid analgesic use upon initiation
20
21
22 7 and the speed of pain relief immediately after initiation in patients with advanced recurrent
23
24
25 8 cancer. Therefore, we designed this study to address the need for sufficient verification of the
26
27
28 9 relationship between psychological barriers and the speed of pain relief.

31
32 10 This study aimed to elucidate the relationship between psychological barriers to strong opioid
33
34
35 11 analgesics use and the speed of pain relief in patients with advanced recurrent cancer. If it is
36
37
38 12 found that cancer pain relief is difficult to achieve in patients hesitant to use strong opioid
39
40
41 13 analgesics, this study may provide important information on how to assuage their reluctance
42
43
44 14 and enable rapid pain improvement.

45 46 47 48 15 **METHODS AND ANALYSIS**

49 50 51 52 16 **Study design**

53
54
55
56
57 17 This is an ongoing, multicentre, longitudinal, observational study. We are investigating the
58
59
60 18 relationship between psychological barriers at the start of treatment and pain relief during the

1 first week of treatment in patients receiving strong opioids for cancer pain. We are also
2 evaluating the relationship between psychological barriers and adverse events associated with
3 the use of strong opioids.

4 **Patient and public involvement**

5 Patients were not invited to collaborate during the study design; therefore, this study protocol
6 was developed without patient and public involvement. The enrolment was started in August
7 2020, and planned to close in October 2021.

8 **Study setting, participants, and recruitment**

9 Recruiting is being performed at five sites in Japan. The inclusion and exclusion criteria are
10 shown in Box 1. The main inclusion criterion is patients aged 20 years or older with distant
11 metastasis or advanced recurrent cancer who receive first treatment with strong opioid
12 analgesics for cancer pain. The main exclusion criteria are patients with difficulties in providing
13 electronic patient-reported outcome (ePRO) data and patients with neuropathic pain. Eligible
14 patients are being invited to participate in the study by investigators at each study site. These
15 patients are being asked to complete an ePRO daily during the first week of treatment.
16 Observation is being discontinued if any of the following occurs: (1) death during observation,
17 (2) the patient's condition deteriorates and the healthcare professional determines that the
18 intervention cannot be continued; (3) the patient withdraws consent; and (4) the investigators

1 judge that observation cannot be continued for any other reason. As a rule, standard pain relief
 2 treatments are being provided at each facility. We are neither restricting the provision of
 3 combination or supportive treatment nor specifying the post-treatment.

4 **Box 1: Eligibility criteria**

Inclusion criteria	
1.	Patients diagnosed with remote metastasis or advanced recurrent cancer by a doctor.
2.	First treatment with strong opioid analgesics for cancer pain.
3.	Patients who are 20 years or older.
4.	Highest intensity of pain in the last 24 hours of an NRS score of 4 or higher.
5.	Patients providing written consent for participating in the study.
Exclusion criteria	
1.	Patients who have difficulty in providing ePRO data (e.g. those who do not have a smartphone or cannot use a tablet).
2.	Patients with cognitive impairments that would hinder PRO administration.
3.	Patients with mental illnesses that would hinder PRO administration.
4.	Patients whose main mechanism of pain is neuropathic.
5.	Other factors that the attending physician deems inappropriate.
ePRO, electronic version of the Patient-Reported Outcomes Questionnaire; NRS, numerical rating scale; PRO, Patient-Reported Outcomes Questionnaire	

5 **Outcome measures**

6 Table 1 shows the timeline of enrolment and assessment. We are using the JBQ-II [20] to assess

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 psychological barriers to opioid analgesic use and the Decision Regret Scale (DRS) [21] to
2 evaluate regret related to decision making. We are using the PRO version of the CTCAE [22]
3 and the CTCAE v5.0 to assess adverse events. We are evaluating pain severity using the Brief
4 Pain Inventory (BPI)-Short Form (SF) [23] and PPG. [24]

5

For peer review only

1
2
3
4 **Table 1: Study timeline**
5
6

Day	Visit 1	Time after initiating opioid therapy							Visit 2
	0 (baseline)	1	2	3	4	5	6	7	8–15
Patient reported outcomes :									
Psychosocial background	●								
JBQ-II	●							●	
PGIS								●	
DRS								●	
PRO-CTCAE	●							●	
BPI-SF (strongest pain in the last 24 hours)	●	●	●	●	●	●	●	●	
PPG	●								
Use of strong opioids before starting base medication with or without rescue medication (outpatients)		●							
Whether any dose of the base strong opioid was missed (outpatients)								●	
Clinician reported outcomes:									
Demographics and medical history	●								
CTCAE v5.0-JCOG	●								●
Presence of increased opioid dosage									●
Presence of opioid switching									●
Use of strong opioids before starting base medication with or without rescue medication (inpatients)									●

Whether any dose of the base strong opioid was missed (inpatients)										•
--	--	--	--	--	--	--	--	--	--	---

1 BPI-SF, Brief Pain Inventory-Short Form; CTCAE, Common Terminology Criteria for
 2 Adverse Events; DRS, Decision Regret Scale; JBQ-II, Japanese version of the Barriers
 3 Questionnaire II; JCOG, Japan Clinical Oncology Group; PGIS, Patient Global Impression of
 4 Severity; PPG, Personalized Pain Goal; PRO, Patient Reported Outcome

5 **Japanese version of the Barriers Questionnaire II**

6 To reflect practical changes in pain management, the BQ, a measure of psychological barriers,
 7 was revised to create the Barriers Questionnaire II (BQ-II). [17] The JBQ-II is the Japanese
 8 version of the BQ-II. It has been validated (Cronbach's $\alpha = 0.92$). [20] The JBQ-II comprises
 9 the following five subscales: barriers related to psychological effects (distrust of symptomatic
 10 treatment), barriers related to fatalism (fateful resignation), barriers related to communication
 11 (loss of intention), barriers related to adverse effects (fear of side effects), and barriers related
 12 to disease progression (escape/defence from illness). Each item is graded on a six-point Likert
 13 scale (0–5). The subscale and total scores (overall barrier) are calculated as the mean of the
 14 scores (0–5) for the relevant items, with higher numbers indicating higher barriers.

15 **Patient Global Impression of Severity**

16 Currently, the cut-off values for classifying the presence and magnitude of psychological
 17 barriers are unknown. We are using the Patient Global Impression of Severity (PGIS) to classify
 18 the participants' JBQ-II scores. The PGIS has not been validated to classify psychological

1
2
3
4 1 barriers. We are grading responses to the item ‘At present, how reluctant are you to use opioids
5
6
7 2 for pain relief?’ using the following seven-point scale: 0, not at all; 1, not reluctant; 2, almost
8
9
10 3 not reluctant; 3, neither; 4, slightly reluctant; 5, reluctant; and 6, extremely reluctant.

14 4 **Decision Regret Scale**

15
16
17
18 5 Regret is a negative emotion experienced when one realises or imagines that one has made the
19
20
21 6 wrong choice. It is a retrospective, unpleasant feeling, and people tend to focus on ‘what is good’
22
23
24 7 rather than ‘what is bad’. It has been reported to be associated with negative emotions, such as
25
26
27 8 disappointment, and involve some aspect of self-blame. [25] We are evaluating regret using the
28
29
30 9 DRS, which measures patient conflict regarding decision making during the treatment process.
31
32
33 10 [26] A Japanese version of the DRS has been developed and validated (Cronbach’s $\alpha = 0.85$).
34
35
36 11 [21] It consists of five items. The total score ranges from 0 to 100, with higher scores indicating
37
38
39 12 greater regret.

43 13 **Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse** 44 45 46 14 **Events**

47
48
49
50
51 15 The National Cancer Institute (NCI)-CTCAE is a standardised tool for assessing adverse events
52
53
54 16 during cancer treatment. However, since grading is based on the clinician’s judgement, it may
55
56
57 17 not be possible to accurately evaluate the patient's condition, especially when subjective aspects
58
59
60 18 are involved. [27] Basch et al. reported a discrepancy between clinicians’ and the patients’

1
2
3
4 1 assessments, indicating that clinicians underestimate CTCAE grades. [28] Therefore, the NCI
5
6
7 2 developed the PRO-CTCAE, which incorporates the concept of PRO into the CTCAE. [29] Its
8
9
10 3 Japanese version has been validated. [22] In this study, we are evaluating the participants' main
11
12
13 4 symptoms, such as pain, and characteristic adverse events related to opioid analgesic use, such
14
15
16 5 as nausea/vomiting, constipation, drowsiness, fatigue, and thirst. We are also evaluating an
17
18
19 6 additional item to measure the psychological burden of using opioid analgesics.
20
21
22

23 7 **Brief Pain Inventory-Short Form**

24
25
26
27 8 The effect of pain on daily life differs from pain intensity. It is related to the amount of pain
28
29
30 9 that hinders activities such as walking, bathing, and sleeping. The BPI is a standardised scale
31
32
33 10 that has been confirmed to be reliable and valid for assessing pain intensity and its effect on
34
35
36 11 daily life. [30] It is a 15-item questionnaire that evaluates pain. Each item is graded on an 11-
37
38
39 12 point scale, with scores ranging from 0 to 10. The Japanese version of this scale has already
40
41
42 13 been validated, and its reliability and usefulness have been established (Cronbach's $\alpha = 0.80$).
43
44
45 14 [23] To decrease the burden on patients related to the number of questions to be answered, we
46
47
48 15 are only using the 'worst pain in the last 24 hours' item of the BPI-SF, based on a report by
49
50
51 16 Atkinson et al. [31]

52 53 54 55 17 **Personalized Pain Goal**

56
57
58
59 18 The numerical rating scale (NRS) is generally used as an index of the average pain over 24
60

1
2
3
4 1 hours and the degree of pain-related disability in daily life (disturbance of life). It is an 11-point
5
6
7 2 scale, with scores ranging from 0 (none) to 10 (the worst possible). A score of ≥ 4 indicates
8
9
10 3 moderate pain/disability, while a score of ≥ 7 indicates severe pain/disability. [32] From the
11
12
13 4 perspective of personalized medicine for the treatment of cancer pain, it is important to involve
14
15
16 5 the patient in treatment goal setting and provide treatment with the aim of achieving those goals.
17
18
19 6 The PPG has recently been used as an outcome measure to determine pain-relief goals in non-
20
21
22 7 Japanese patients with cancer. [33] The PPG helps patients set a personalized pain-relief goal
23
24
25 8 using the following question: 'At what level would you feel comfortable with pain? [24]'. In
26
27
28 9 our study, patients are being asked to use the NRS to indicate their pain treatment goals. Pain
29
30
31 10 treatment is considered to be successful (achievement of the PPG) if the patient's NRS score
32
33
34 11 for pain at the time of assessment is below the PPG.

12 **Others**

13 Since strong opioid use during the study period might affect the time to PPG achievement, the
14 following items are being investigated: (1) whether any dose of the base strong opioid was
15 missed, (2) presence of increased opioid dosage, (3) presence of opioid switching, and (4) use
16 of strong opioids before starting base medication with or without rescue medication.

17 **Sample size**

18 Since this is an observational study conducted to form a hypothesis rather than a confirmatory

1 study conducted to test it, [34] the sample size is focus on feasibility and is based on the number
2 of patients receiving strong opioid analgesics at the main medical institution. At Yokohama
3 City University Medical Center, 378 patients started receiving strong opioid analgesics in 2019
4 (total oral and injection, excluding local use). Among them, 60% met the eligibility criteria, and
5 60% of them were assumed to be able to express consent, which leads us to estimate that 136
6 people could enrol into this study within 1 year. In addition, it is expected that 10–40 patients
7 will be enrolled annually at Tokyo Medical University Hospital, National Cancer Centre
8 Hospital East, Yokohama-Minami Kyosai Hospital, and Kameda General Hospital. Based on
9 these estimates, we set the sample size target at 200.

10 **Data collection and timeline**

11 We are using the electronic data capture (EDC) systems Viedoc 4 and ViedocMe (Viedoc
12 Technologies, Sweden) and ePRO, to enrol the participants and collect their data. During
13 enrolment, the investigators input their personal accounts and passwords into the system.
14 Investigators at each site use the EDC system to input data into an electronic case report form.
15 Patients are being administered the PROs using an ePRO application on their device
16 (smartphone, tablet, or personal computer) at eight time points: at baseline and on days one to
17 seven. The patients may register their phone number or e-mail address in the EDC system and
18 use the ePRO reminder function. The investigators are providing the patients with details about

1
2
3
4 1 the trial. After obtaining patient consent, data regarding each patient's psychosocial
5
6
7 2 background; JBQ-II, PRO-CTCAE, and BPI-SF scores; and PPG are collected from their
8
9
10 3 electronic device. Data regarding demographics, medical history, and CTCAE v5.0-JCOG
11
12
13 4 score are collected, entered into the web-based EDC system at the study site, and linked to the
14
15
16 5 baseline PRO data. After starting to receive opioids, each patient is asked to record their BPI-
17
18
19 6 SF (worst pain in the last 24 hours) score daily for 7 days. On the last day, each patient is
20
21
22 7 administered the JBQ-II, PGIS, DRS, and PRO-CTCAE. Each patient's CTCAE v5.0-JCOG
23
24
25 8 data is collected by an investigator at the time of their next visit (days 8–15). In addition, we
26
27
28 9 are recording each patient's use of strong opioid medication prior to starting base medication
29
30
31 10 and whether any dose of the strong base opioid has been missed. The study timeline is presented
32
33
34 11 in Table 1.

12 **Data monitoring**

13 The data centre is located at the Department of Practical Pharmacy, School of Pharmacy, Tokyo
14 University of Pharmacy and Life Sciences, Tokyo, Japan. No personally identifiable
15 information is being entered into the EDC system, and the participating sites are not
16 communicating personal information to the data centre. Since this study involves data collection
17 using an EDC system, the data is stored on the server during the study period. After the end of
18 the study period, the data exported from the EDC system will be stored at the data centre until

1
2
3
4 1 presentation or publication. Following this, the data will be stored at the research secretariat
5
6
7 2 and data centre. Monitoring is being performed to ensure that the study is conducted according
8
9
10 3 to the protocol and that the data is collected accurately. Central monitoring is being performed
11
12
13 4 by the data centre based on the EDC data collected. The data centre has been submitting
14
15
16 5 monthly monitoring reports to the researchers, is sharing information with the researchers at all
17
18
19 6 the study sites, and is striving for improvement. There is no data monitoring committee, and
20
21
22 7 auditing has not been planned for this study.
23
24
25

26 8 **Harm**

27
28
29
30 9 This is a non-intervention observational study with low invasiveness. We expect no serious
31
32
33 10 harm to occur. However, the questionnaire contents may cause mental strain to the participants.
34
35
36 11 Consent may be withdrawn even while filling the questionnaire, and the study is explained in
37
38
39 12 detail to the participants prior to enrolment.
40
41
42

43 13 **Statistical analysis**

44
45
46
47 14 The primary outcome is the Japanese version of the Barriers Questionnaire-II (JBQ-II) score at
48
49
50 15 baseline. The secondary outcomes are the relationships between the total JBQ-II score and the
51
52
53 16 time to Personalized Pain Goal (PPG) achievement, JBQ-II scores at baseline and at the second
54
55
56 17 visit, changes in JBQ-II scores, and PPG achievement rate on day 7. In addition, the proportion
57
58
59 18 of adverse events will be calculated using the Patient-Reported Outcomes (PRO)- Common
60

1 Terminology Criteria for Adverse Events (CTCAE) and CTCAE v5.0- Japan Clinical Oncology
2 Group (JCOG) for safety analysis. The mean JBQ-II score at baseline will be calculated for all
3 patients, and its 95% confidence interval will be estimated. The relationships between the total
4 JBQ-II score and the PPG achievement period, JBQ-II scores at baseline and at the second visit,
5 changes in JBQ-II scores, and PPG achievement rate on day seven will be examined. Patients
6 will be grouped based on their PGIS scores, and the difference between the DRS score and PPG
7 achievement rate between the two groups will be estimated and tested. The relationship between
8 the JBQ-II and trends in pain scores will be investigated. In addition, the proportion of adverse
9 events will be calculated using the PRO-CTCAE and CTCAE v5.0-JCOG for safety analysis.

10 **ETHICS AND DISSEMINATION**

11 **Research ethical approval**

12 The study is being performed in accordance with the Declaration of Helsinki; Ethical
13 Guidelines for Medical and Health Research Involving Human Subjects published by the
14 Japanese Ministry of Education, Science and Technology and the Ministry of Health, Labour,
15 and Welfare; and the modified Act on the Protection of Personal Information. The protocol was
16 approved by the ethics committee (approval ID B200600091) of Yokohama City University on
17 24 August 2020. The protocol version was 1.1 in November 2020. The protocol has been
18 reviewed by the institutional review board at the following study sites: Tokyo Medical

1
2
3
4 1 University Hospital, Yokohama Minami Kyou Sai Hospital, National Cancer Center Hospital
5
6
7 2 East, and Kameda General Hospital.
8
9

10 11 3 **Consent** 12 13 14

15 4 Before enrolment, an investigator explains the details of the study to the patients and gives them
16
17
18 5 time to think about it. All participants are informed of their right to withdraw their consent
19
20
21 6 without prejudice. The study will be conducted after obtaining written consent from all the
22
23
24 7 patients.
25
26
27

28 8 **Trial registration** 29 30 31

32 9 This trial has been registered at the University Hospital Medical Information Network Clinical
33
34
35 10 Trials Registry (UMIN000042443).
36
37
38
39

40 11 **Access to data** 41 42 43

44 12 Investigators can only access the case data collected at their respective study sites. Only clinical
45
46
47 13 data managers at the data centre have access to reported case data through the EDC system
48
49
50 14 during the study period.
51
52
53

54 15 **Dissemination policy** 55 56 57 58 59 60

1 The results of this study will be presented at conferences and published in national and
2 international peer-reviewed medical journals.

3 **DISCUSSION**

4 To date, most studies on psychological barriers to analgesia have not specifically studied the
5 use of strong opioid analgesics. The BAROC is an exploratory study investigating the
6 relationship between psychological barriers and improvement in pain. It is important to use
7 PROs, as pain improvement contributes to health-related quality of life. [35-38] Psychological
8 barriers may be influenced by opioid switching and analgesic use before the commencement of
9 regular strong opioid analgesics use. [17 35 39] These data are also being collected using the
10 EDC system.

11 The BAROC is the first multicentre study in Japan to evaluate the relationship between
12 psychological barriers and cancer pain. The study sites include university hospitals, specialised
13 cancer hospitals, and community hospitals, and it is expected that the enrolled patients will have
14 diverse demographics. One of the characteristics of this study is that eligibility is not limited by
15 performance status. This means that patients with a poor performance status may be eligible to
16 participate in this study. Patients on strong opioid analgesics often have a poor performance
17 status, and our data will reflect actual clinical practice.

1
2
3
4 1 Although the use of strong opioid analgesics can be beneficial in treating cancer pain, it can
5
6
7 2 also cause adverse events. Nausea and drowsiness commonly occur during opioid induction.
8
9
10 3 There is concern that these symptoms may lead to decreased adherence and, therefore,
11
12
13 4 interruption of pain treatment. In addition, the occurrence of adverse events can cause anxiety,
14
15
16 5 worry, and other psychological burdens, amplifying resistance to opioid analgesic use. In this
17
18
19 6 study, data on adverse event occurrence is being collected not only from physicians but also
20
21
22 7 from the patients themselves using the PRO-CTCAE. Because adverse events and
23
24
25 8 psychological barriers are closely related, precision in adverse event assessment is required.
26
27
28 9 Thus, it is important to use the PRO-CTCAE in addition to the CTCAE to consider the
29
30
31 10 relationship between psychological barriers and adverse events and enable high-quality adverse
32
33
34 11 event assessment.
35
36
37
38 12 Von Roenn et al. used case scenarios to survey 897 physicians from the Eastern Cooperative
39
40
41 13 Oncology Group about the prevalence of pain in cancer patients and physicians' perceptions of
42
43
44 14 managing pain. Although the case scenarios described patients with moderate to severe pain,
45
46
47 15 51% of physicians reported that they would prescribe 'weak' opioids. [40] However, for cancer
48
49
50 16 patients with moderate pain, low doses of morphine can result in a significantly greater
51
52
53 17 reduction in pain intensity than weaker opioids with similarly good tolerability and early effects.
54
55
56 18 [41] Therefore, it is important to remove barriers to introducing strong opioids at an early stage
57
58
59 19 and achieve rapid pain relief.
60

1
2
3
4 1 This study protocol has several limitations. First, this is an exploratory hypothesis-generating
5
6
7 2 observational study. The number of participants was not determined using statistical methods
8
9
10 3 and was based on the caseload of the participating institutions. Second, because this is an
11
12
13 4 observational study, we are neither specifying the explanation to be provided to the patients
14
15
16 5 before initiation of strong opioid analgesic use nor are we specifying the setting in which this
17
18
19 6 explanation is to be provided; each facility is following its protocol in this regard. Psychological
20
21
22 7 barriers may fluctuate depending on the method of explanation and the environment at that
23
24
25 8 time. There are situations in which treatment must be started despite significant barriers, as not
26
27
28 9 using opioid analgesics even when the pain becomes severe can significantly reduce quality of
29
30
31 10 life. This study was conducted in a population that has already started treatment. Therefore, the
32
33
34 11 results from this study cannot be applied to populations in whom strong opioid analgesics have
35
36
37 12 not yet been considered. Third, we exclude patients with cognitive impairment or mental illness
38
39
40 13 and those who cannot operate a smartphone or tablet from this study. Therefore, we will not be
41
42
43 14 able to enrol all patients receiving strong opioid analgesics. Most of the excluded participants
44
45
46 15 are likely to be older adults. Finally, due to the coronavirus disease-2019 pandemic, it may be
47
48
49 16 difficult to recruit patients due to restrictions on hospital functions and patients' reluctance to
50
51
52 17 receive care. As a result, enrolment for this study may need to be delayed.

53
54
55
56 18 The BAROC study may provide important information that may help reduce psychological
57
58
59 19 barriers to cancer pain relief in patients who are reluctant to use strong opioid analgesics.
60

- 1
2
3
4 1 Clarifying the relationship between the achievement of pain relief goals and psychological
5
6
7 2 barriers at the time of introduction of strong opioid analgesics will provide basic data for future
8
9
10 3 interventional studies, encourage education of healthcare providers for reducing psychological
11
12
13 4 barriers in advance to enable rapid pain amelioration, and contribute to improving the quality
14
15
16 5 of cancer pain treatment.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1 **Acknowledgements**

2 We are grateful to Mashiko T and Miyaji T for their long-term collaboration and advice. The
3 authors thank in advance all the patients, investigators, and institutions involved in this study.

4 We also thank Editage (www.editage.com) for providing writing support.

5 **Contributors**

6 TT contributed to trial conception and is the principal investigator.

7 TT, TF, TK, AK, and HH contributed to the study design.

8 TF, TK, and TY contributed to data management. TK and TY planned the data analysis.

9 Data analysis and interpretation will be conducted by TT, TF, TK, and TY.

10 TT, AM, KA, TS, TI, and JK acquired the data.

11 All authors have read and approved the final manuscript and meet the criteria for authorship as
12 established by the International Committee of Medical Journals Editors.

13 **Funding**

14 This research received no specific grant from any funding agency in the public, commercial, or
15 not-for-profit sectors.

1
2
3
4 **1 Competing interests**
5
6
7

8 2 None declared.
9
10

11
12 **3 Patient consent for publication**
13
14

15
16 4 Not required.
17
18

19
20
21 **5 Provenance and peer review**
22
23

24
25 6 Not commissioned; externally peer-reviewed.
26
27

28
29 **7 Open access**
30
31

32
33 8 This is an open-access article distributed in accordance with the Creative Commons Attribution
34

35
36 9 Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt,
37

38
39 10 build upon this work non-commercially, and license their derivative works on different terms,
40

41
42 11 provided the original work is properly cited, appropriate credit is given, any changes made
43

44
45 12 indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.
46
47

48
49 **13 ORCID iD**
50
51

52
53 14 Takehiko Tsuno <https://orcid.org/0000-0002-5844-1226>
54

55
56
57 15 Tatsuhiro Fujimiya <https://orcid.org/0000-0001-8198-7465>
58
59
60

1
2
3
4 1 Takashi Kawaguchi <https://orcid.org/0000-0003-2446-7716>
5
6
7

8 2 **References**
9
10

- 11 3 1 Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF et al.
12 4 Global, regional, and national cancer incidence, mortality, years of life lost, years lived
13 5 with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A
14 6 systematic analysis for the global burden of disease study. *JAMA Oncol* 2018;4:1553–
15 7 68.
16 8 2 Horii M, Matsuda T, Shibata A, et al. Cancer incidence and incidence rates in Japan in
17 9 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer
18 10 Incidence in Japan (MCIJ) project. *Jpn J Clin Oncol* 2015;45:884–91.
19 11 3 Bruera E, Kim HN. Cancer pain. *JAMA* 2003;290:2476–9.
20 12 4 Yamagishi A, Morita T, Miyashita M, et al. Pain intensity, quality of life, quality of
21 13 palliative care, and satisfaction in outpatients with metastatic or recurrent cancer: a
22 14 Japanese, nationwide, region-based, multicenter survey. *J Pain Symptom Manage*
23 15 2012;43:503–14.
24 16 5 Jacobsen R, Møldrup C, Christrup L, et al. Patient-related barriers to cancer pain
25 17 management: a systematic exploratory review. *Scand J Caring Sci* 2009;23:190–208.
26 18 6 Ward SE, Goldberg N, Miller-McCauley V, et al. Patient-related barriers to
27 19 management of cancer pain. *Pain* 1993;52:319–24.
28 20 7 Al-Atiyyat NMH, Vallerand AH. Patient-related attitudinal barriers to cancer pain
29 21 management among adult Jordanian patients. *Eur J Oncol Nurs* 2018;33:56–61.
30 22 8 Ell K, Sanchez K, Vourlekis B, et al. Depression, correlates of depression, and receipt
31 23 of depression care among low-income women with breast or gynecologic cancer. *J Clin*
32 24 *Oncol* 2005;23:3052–60.
33 25 9 Kwon JH. Overcoming barriers in cancer pain management. *J Clin Oncol*
34 26 2014;32:1727–33.
35 27 10 Nguyen LM, Rhondali W, De la Cruz M, et al. Frequency and predictors of patient
36 28 deviation from prescribed opioids and barriers to opioid pain management in patients
37 29 with advanced cancer. *J Pain Symptom Manage* 2013;45:506–16.
38 30 11 Chen CH, Tang ST, Chen CH. Meta-analysis of cultural differences in Western and
39 31 Asian patient-perceived barriers to managing cancer pain. *Palliat Med* 2012;26:206–21.
40 32 12 Berterame S, Erthal J, Thomas J, et al. Use of and barriers to access to opioid analgesics:
41 33 a worldwide, regional, and national study. *Lancet* 2016;387:1644–56.
42 34 13 Akiyama M, Takebayashi T, Morita T, et al. Knowledge, beliefs, and concerns about
43 35 opioids, palliative care, and homecare of advanced cancer patients: a nationwide survey

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

in Japan. *Support Care Cancer* 2012;20:923–31.

14 Morita T, Miyashita M, Shibagaki M, et al. Knowledge and beliefs about end-of-life care and the effects of specialized palliative care: a population-based survey in Japan. *J Pain Symptom Manage* 2006;31:306–16.

15 Gunnarsdottir S, Serlin RC, Ward S. Patient-related barriers to pain management: the Icelandic Barriers Questionnaire II. *J Pain Symptom Manage* 2005;29:273–85.

16 Ward SE, Hernandez L. Patient-related barriers to management of cancer pain in Puerto Rico. *Pain* 1994;58:233–38.

17 Gunnarsdottir S, Donovan HS, Serlin RC, et al. Patient-related barriers to pain management: the Barriers Questionnaire II (BQ-II). *Pain* 2002;99:385–96.

18 Lin CC, Ward SE. Patient-related barriers to cancer pain management in Taiwan. *Cancer Nurs* 1995;18:16–22.

19 Gunnarsdottir S, Sigurdardottir V, Kloke M, et al. A multicenter study of attitudinal barriers to cancer pain management. *Support Care Cancer* 2017;25:3595–602.

20 Sakakibara N, Komatsu H, Takahashi M, et al. Validation of the Japanese version of the barriers questionnaire II in cancer pain management: a cross-sectional study. *BMC Palliat Care* 2020;19:102.

21 Tanno K, Bito S, Isobe Y, et al. Validation of a Japanese version of the decision regret scale. *J Nurs Meas* 2016;24:E44–54.

22 Kawaguchi T, Azuma K, Sano M, et al. The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events. *J Patient Rep Outcomes* 2017;2:2.

23 Uki J, Mendoza T, Cleeland CS, et al. A brief cancer pain assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory--BPI-J. *J Pain Symptom Manage* 1998;16:364–73.

24 Tagami K, Kawaguchi T, Miura T, et al. The association between health-related quality of life and achievement of personalized symptom goal. *Support Care Cancer* 2020;28:4737–43.

25 Zeelenberg M, Pieters R. A Theory of Regret Regulation 1.0. *J Con Psychol* 2007;17:3–18.

26 Brehaut JC, O’Connor AM, Wood TJ, et al. Validation of a decision regret scale. *Med Decis Making* 2003;23:281–92.

27 Basch E. The missing voice of patients in drug-safety reporting. *N Engl J Med* 2010;362:865–9.

28 Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. *Lancet Oncol* 2006;7:903–9.

29 Basch E, Dueck AC, Rogak LJ, et al. Feasibility of implementing the patient-reported

- 1 outcomes version of the common terminology criteria for adverse events in a
2 multicenter trial: NCCTG N1048. *J Clin Oncol* 2018;N1048:JCO2018788620.
- 3 30 Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann*
4 *Acad Med Singapore* 1994;23:129–38.
- 5 31 Atkinson TM, Mendoza TR, Sit L, et al. The Brief Pain Inventory and its ‘pain at its
6 worst in the last 24 hours’ item: clinical trial endpoint considerations. *Pain Med*
7 2010;11:337–46.
- 8 32 Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or
9 severe? Grading pain severity by its interference with function. *Pain* 1995;61:277–84.
- 10 33 Dalal S, Hui D, Nguyen L, et al. Achievement of personalized pain goal in cancer
11 patients referred to a supportive care clinic at a comprehensive cancer center. *Cancer*
12 2012;118:3869–77.
- 13 34 Vandembroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of
14 Observational Studies in Epidemiology (STROBE): explanation and elaboration.
15 *Epidemiology* 2007;18:805–35.
- 16 35 Mercadante S, Adile C, Tirelli W, et al. Barriers and adherence to pain management in
17 advanced cancer patients. *Pain Pract* 2021;21:388–93.
- 18 36 Wang XS, Cleeland CS, Mendoza TR, et al. The effects of pain severity on health-
19 related quality of life: a study of Chinese cancer patients. *Cancer* 1999;86:1848–55.
- 20 37 Park KU. Assessment of change of quality of life in terminally ill patients under cancer
21 pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in
22 a Korean sample. *Oncology* 2008;74;Suppl 1:7–12.
- 23 38 Glaser AW, Fraser LK, Corner J, et al. Patient-reported outcomes of cancer survivors
24 in England 1–5 years after diagnosis: a cross-sectional survey. *BMJ Open* 2013;3.
- 25 39 Bağcıvan G, Tosun N, Kömürçü S, et al. Analysis of patient-related barriers in cancer
26 pain management in Turkish patients. *J Pain Symptom Manage* 2009;38:727–37.
- 27 40 Von Roenn JH, Cleeland CS, Gonin R, et al. Physician attitudes and practice in cancer
28 pain management. A survey from the Eastern Cooperative Oncology Group. *Ann Intern*
29 *Med* 1993;119:121–6.
- 30 41 Bandieri E, Romero M, Ripamonti CI, et al. Randomized trial of low-dose morphine
31 versus weak opioids in moderate cancer pain. *J Clin Oncol* 2016;34:436–42.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract Page 1 (b) Provide in the abstract an informative and balanced summary of what was done and what was found Page 3-5
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 6-8
Objectives	3	State specific objectives, including any prespecified hypotheses Page 8,9
Methods		
Study design	4	Present key elements of study design early in the paper Page 9,10
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 10,11
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Page 11 <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls N/A <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants N/A (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed N/A <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 11,12
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 13-17
Bias	9	Describe any efforts to address potential sources of bias N/A
Study size	10	Explain how the study size was arrived at Page 17,18
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why N/A
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding Page 13 (b) Describe any methods used to examine subgroups and interactions N/A (c) Explain how missing data were addressed N/A (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed N/A <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed N/A <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy N/A (e) Describe any sensitivity analyses N/A

Continued on next page

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed <input type="text" value="N/A"/> (b) Give reasons for non-participation at each stage <input type="text" value="N/A"/> (c) Consider use of a flow diagram <input type="text" value="N/A"/>
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders <input type="text" value="N/A"/> (b) Indicate number of participants with missing data for each variable of interest <input type="text" value="N/A"/> (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) <input type="text" value="N/A"/>
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <input type="text" value="N/A"/> <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <input type="text" value="N/A"/> <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures <input type="text" value="N/A"/>
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included <input type="text" value="N/A"/> (b) Report category boundaries when continuous variables were categorized <input type="text" value="N/A"/> (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period <input type="text" value="N/A"/>
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses <input type="text" value="N/A"/>
Discussion		
Key results	18	Summarise key results with reference to study objectives <input type="text" value="N/A"/>
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias <input type="text" value="Page 25"/>
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence <input type="text" value="N/A"/>
Generalisability	21	Discuss the generalisability (external validity) of the study results <input type="text" value="N/A"/>
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based <input type="text" value="Page 27"/>

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Psychological barriers to the use of opioid analgesics for treating pain in patients with advanced recurrent cancer (BAROC): protocol for a multicentre cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054914.R2
Article Type:	Protocol
Date Submitted by the Author:	04-Feb-2022
Complete List of Authors:	<p>Tsuno, Takehiko; Yokohama City University Medical Center, Department of Pharmacy; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Analytical Chemistry Fujimiya, Tatsuhiro; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Practical Pharmacy Kawaguchi, Takashi; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Practical Pharmacy Yanaizumi, Ryota; Yokohama City University Medical Center, Department of Anesthesiology Kojima, Keiko; Yokohama City University Medical Center, Department of Palliative Medicine Miyasato, Akime; Tokyo Medical University Hospital, Department of Pharmacy Kanao, Azuma; Tokyo Medical University Hospital, Department of Pharmacy Saeki, Tomoya; Yokohama Minami Kyou Sai Hospital, Department of Pharmacy Mawatari, Hironori; Yokohama Minami Kyou Sai Hospital, Department of Palliative and Supportive Care Igarashi, Takashi; National Cancer Center-Hospital East, Department of Pharmacy Miura, Tomofumi; National Cancer Center-Hospital East, Department of Palliative Medicine Ogura, Hiroyuki; Kameda Medical Center, Department of Pharmacy Kondo, Junichi; Yokohama City University Medical Center, Department of Pharmacy Tanoue, Tadashi; Tokyo Medical University Hospital, Department of Palliative Medicine Hamada, Hiroshi; Tokyo Medical University Hospital, Department of Palliative Medicine Oyama, Yu; Kameda Medical Center, Department of Medical Oncology Kotani, Akira; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Analytical Chemistry Yamaguchi, Takuhiro; Tohoku University Graduate School of Medicine, Division of Biostatistics Hakamata, Hideki; Tokyo University of Pharmacy and Life Science School of Pharmacy, Department of Analytical Chemistry</p>
Primary Subject	Palliative care

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Heading	
Secondary Subject Heading:	Anaesthesia, Oncology, Patient-centred medicine, Pharmacology and therapeutics
Keywords:	Adverse events < THERAPEUTICS, Cancer pain < ONCOLOGY, Anaesthesia in oncology < ANAESTHETICS

SCHOLARONE™
Manuscripts

1
2
3
4 1 **Psychological barriers to the use of opioid analgesics for treating pain in patients with**
5
6
7 2 **advanced recurrent cancer (BAROC): protocol for a multicentre cohort study**
8
9

10
11 3 **Authors:**
12

13 4 Takehiko Tsuno ^{1, 13}, Tatsuhiro Fujimiya ², Takashi Kawaguchi ², Ryota Yanaizumi ³, Keiko
14 5 Kojima ⁴, Akime Miyasato ⁵, Kanako Azuma ⁵, Tomoya Saeki ⁶, Hironori Mawatari ⁷,
15 6 Takashi Igarashi ⁸, Tomofumi Miura ⁹, Hiroyuki Ogura ¹⁰, Junichi Kondo ¹, Tadashi Tanoue
16 7 ¹¹, Hiroshi Hamada ¹¹, Yu Oyama ¹², Akira Kotani ¹³, Takuhiro Yamaguchi ¹⁴, Hideki
17 8 Hakamata ¹³
18
19
20
21

22 9 **Affiliations:**
23

- 24 10 1. Department of Pharmacy, Yokohama City University Medical Center, Yokohama, Japan
25
26 11 2. Department of Practical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and
27 12 Life Sciences, Tokyo, Japan
28
29 13 3. Department of Anesthesiology, Yokohama City University Medical Center, Yokohama,
30 14 Japan
31
32 15 4. Department of Palliative Medicine, Yokohama City University Medical Center, Yokohama,
33 16 Japan
34
35 17 5. Department of Pharmacy, Tokyo Medical University Hospital, Tokyo, Japan
36
37 18 6. Department of Pharmacy, Yokohama Minami Kyousai Hospital, Yokohama, Japan.
38
39 19 7. Department of Palliative and Supportive Care, Yokohama Minami Kyousai Hospital,
40 20 Yokohama, Japan.
41
42 21 8. Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan.
43
44 22 9. Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, Japan
45
46 23 10. Department of Pharmacy, Kameda Medical Center, Chiba, Japan.
47
48 24 11. Department of Palliative Medicine, Tokyo Medical University Hospital, Tokyo, Japan
49
50 25 12. Department of Medical Oncology, Kameda Medical Center, Chiba, Japan
51
52
53
54
55
56
57
58
59
60

1
2
3 1 13. Department of Analytical Chemistry, School of Pharmacy, Tokyo University of Pharmacy
4 2 and Life Sciences, Tokyo, Japan

5
6
7 3 14. Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan
8
9

10 4
11
12
13 5 **Corresponding Author:**

14 6 Takashi Kawaguchi

15 7 Department of Practical Pharmacy,

16 8 Tokyo University of Pharmacy and Life Sciences,

17 9 1432-1, Horinouchi, Hachioji-city, Tokyo, 192-0392, Japan.

18 10 Telephone: +81-042-676-1521

19 11 E-Mail: tkawa@toyaku.ac.jp
20
21
22
23
24

25 13 **Word count:** 3988

26
27 14 **Key Words:** adverse events; cancer pain; strong opioids; psychological barriers
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **ABSTRACT**

2 **Introduction**

3 Opioid analgesics are essential for treating cancer pain. However, patients are sometimes
4 reluctant to use them because of concerns about addiction and dependence. Rapid pain relief
5 following opioid administration may help overcome the psychological barriers to opioid
6 analgesic use. This study aims to determine the relationship between psychological resistance
7 to strong opioid analgesic use and pain amelioration speed in patients with advanced recurrent
8 cancer.

9 **Methods and analysis**

10 This ongoing, multicentre, observational study enrolls patients aged 20 years or older with
11 distant metastasis or advanced recurrent cancer receiving strong opioid analgesics for cancer
12 pain for the first time. All participants, both inpatient and outpatient, were recruited from five
13 Japanese hospitals. We are investigating the relationship between psychological barriers at the
14 start of treatment and pain relief during the first week of treatment in these patients. The primary
15 outcome is the Japanese version of the Barriers Questionnaire-II score at baseline. The
16 secondary outcomes are the relationships between psychological barriers to strong opioid
17 analgesic use and changes in pain over time. The participants are asked to fill out an electronic
18 patient-reported outcome daily during the first week of treatment. The sample size was

1
2
3
4 1 determined based on the number of patients in the year prior to study commencement who used
5
6
7 2 strong opioid analgesics, met the eligibility criteria, and could be expected to consent to
8
9
10 3 participate in the study.
11
12
13

14 **Ethics and dissemination**

15
16
17

18 5 The study protocol was approved by the ethics committee (approval ID B200600091) of
19
20
21 6 Yokohama City University on 24 August 2020. The protocol has been reviewed by the
22
23
24 7 institutional review boards at the four participating study sites. The results will be published in
25
26
27 8 a peer-reviewed journal and will be presented at a relevant meeting.
28
29
30

31 **Trial registration number**

32
33
34

35 10 UMIN000042443
36
37
38
39
40
41
42
43

44 **Strengths and limitations of the study**

45
46
47

- 48 13 ➤ This is the first multicentre observational study to evaluate psychological barriers to the
49
50
51 14 use of strong opioids in Japan.
52
53
54 15 ➤ Adverse events related to opioid analgesic use are assessed using the Patient-Reported
55
56
57 16 Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-
58
59
60 17 CTCAE) and CTCAE v5.0-Japan Clinical Oncology Group.

- 1
2
3
4 1 ➤ A limitation of this study is its short observation period, which leads to an inability to
5
6
7 2 confirm long-term variations in psychological barriers.
8
9
10
11 3
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1 INTRODUCTION

2 In 2017, there were 24.5 million incident cancer cases worldwide, and 9.6 million of people
3 who died of cancer. [1] The incidence of cancer increased by 33% from 2007 to 2017. In 2009,
4 there were 775,601 patients with cancer in Japan. [2] Cancer pain is the most concerning
5 symptom of patients with cancer, with approximately 80% of patients with advanced cancer
6 experiencing moderate to severe pain. [3] Japanese studies have examined the percentage of
7 patients with cancer requiring and undergoing treatment for pain relief. [4] In a survey, 60% of
8 patients with cancer had pain, with 20% having moderate to severe pain. [5] Based on the
9 prevalence of cancer in Japan, it is estimated that approximately 155,000 Japanese patients have
10 moderate to severe pain and require opioid analgesics.

11 Patients with cancer often hesitate to manage their cancer pain using opioid analgesics. Their
12 hesitation-related perceptions include concerns about addiction, gradual loss of effectiveness,
13 severe side effects, anxiety due to pain predicting disease progression, and the idea that
14 physicians are reluctant to talk about pain. [6] The Barriers Questionnaire (BQ) quantitatively
15 measures factors related to patients' hesitation regarding opioid use. This scale was used to
16 evaluate 270 patients with cancer, and it was found that 37%–85% of them were concerned
17 about addiction and believed that good patients do not complain about pain and side effects.
18 Additionally, older individuals, those from low-income households, and those with low levels

1 of education had higher concerns related to medical narcotics. [7] Furthermore, a relationship
2 between the presence of barriers and pain intensity has also been reported. [8] Moreover,
3 patients' mental anguish is positively correlated with pain, [9] and opioid analgesics may be
4 insufficient for pain management depending on the patients' mental state.

5 A review investigating the barriers to cancer pain management related to healthcare
6 professionals, patients, and systems [10] revealed that patient-related barriers included
7 cognitive and emotional barriers and treatment adherence. Cognitive barriers included
8 underreporting of symptoms to doctors and painkiller-related misunderstandings. Large barriers
9 were associated with race, sex, and poor medication adherence. [11] In particular, a meta-
10 analysis showed that Asians have greater barriers to cancer pain progression, tolerance, and
11 lethality than Westerners. [12] A survey conducted across 214 countries by the International
12 Narcotics Control Board revealed that Japanese individuals consumed fewer medical narcotics
13 per million people per day than those from other countries (1,192 vs 3,027, respectively).
14 Barriers to narcotic use included lack of training and awareness among healthcare professionals,
15 concern regarding dependency, limited financial resources, procurement issues, cultural
16 behaviour, fear of diversion, and international trade control and regulation. [13] Using a
17 questionnaire, regulatory authorities of various countries found a high percentage of patients
18 (56%) with concerns about dependency in East Asia, which includes Japan. This suggests that
19 the higher the number of reported barriers, the lower the opioid analgesic use. [13]

1
2
3
4 1 A Japanese questionnaire study found that 28% of patients with advanced and recurrent cancer
5
6
7 2 believe that opioid analgesic use shortens their lifespan and causes addiction. [14] A national
8
9
10 3 survey of 5,000 people revealed that 27%–38% of participants reported that opioids shorten
11
12
13 4 lifespan, while 24%–33% reported that opioids cause addiction. [15] This emphasises the need
14
15
16 5 to thoroughly consider barriers when initiating treatment with opioids in Japanese patients.
17
18
19 6 Despite barriers, acceptance of opioid use for pain relief is expected to improve through the
20
21
22 7 practice of high-quality palliative care, pain relief following administration of narcotic
23
24
25 8 medication, and improved confidence in drug safety. [15] Consequently, we believe that pain
26
27
28 9 relief immediately after drug administration is important for breaking these barriers and that
29
30
31 10 patients who confidently use opioid analgesics will quickly achieve the optimal dose and
32
33
34 11 experience immediate pain relief. Patients' pain and mental state fluctuate daily and diurnally,
35
36
37 12 and comparing pre- and post-intervention findings may lead to inaccurate results. [9] A detailed
38
39
40 13 assessment of the speed of pain relief requires repeated evaluation over time.

41
42
43
44 14 Several studies have shown a positive correlation between psychological barriers and pain level,
45
46
47 15 possibly due to inadequate analgesic use. [8, 16] Furthermore, psychological barriers were
48
49
50 16 lower when analgesics appropriate for the level of pain were used than when inadequate
51
52
53 17 analgesics were used. However, the use of strong opioid analgesics has not been specifically
54
55
56 18 studied. [17-19] A study conducted at six medical centres in three countries that regulate the
57
58
59 19 use of strong opioid analgesics examined psychological barriers in patients who had been using
60

1
2
3
4 1 strong opioid analgesics for more than 72 hours and showed that patients who had been using
5
6
7 2 strong opioid analgesics for a short period reported higher barrier scores than those who had
8
9
10 3 been using them for a long time. [20] Therefore, it is important for future cancer pain treatment
11
12
13 4 to identify changes in psychological barriers during and after initiation of use of strong opioid
14
15
16 5 analgesics. However, these are cross-sectional studies, and, to date, only a few studies have
17
18
19 6 investigated the relationship between psychological resistance to strong opioid analgesic use
20
21
22 7 upon initiation and the speed of pain relief immediately after initiation in patients with advanced
23
24
25 8 recurrent cancer. Therefore, we designed this study to address the need for sufficient
26
27
28 9 verification of the relationship between psychological barriers and the speed of pain relief.

31
32 10 This study aimed to elucidate the relationship between psychological barriers to strong opioid
33
34
35 11 analgesics use and the speed of pain relief in patients with advanced recurrent cancer. If it is
36
37
38 12 found that cancer pain relief is difficult to achieve in patients hesitant to use strong opioid
39
40
41 13 analgesics, this study may provide important information on how to assuage their reluctance
42
43
44 14 and enable rapid pain improvement.

48 15 **METHODS AND ANALYSIS**

52 16 **Study design**

53
54
55
56
57 17 This is an ongoing, multicentre, longitudinal, observational study. We are investigating the
58
59
60 18 relationship between psychological barriers at the start of treatment and pain relief during the

1 first week of treatment in patients receiving strong opioids for cancer pain. We are also
2 evaluating the relationship between psychological barriers and adverse events associated with
3 the use of strong opioids.

4 **Patient and public involvement**

5 Patients were not invited to collaborate during the study design; therefore, this study protocol
6 was developed without patient and public involvement. The enrolment was started in August
7 2020, and planned to close in October 2021.

8 **Study setting, participants, and recruitment**

9 Recruiting is being performed at five sites in Japan. The inclusion and exclusion criteria are
10 shown in Box 1. The main inclusion criterion is patients aged 20 years or older with distant
11 metastasis or advanced recurrent cancer who receive first treatment with strong opioid
12 analgesics for cancer pain. The main exclusion criteria are patients with difficulties in providing
13 electronic patient-reported outcome (ePRO) data and patients with neuropathic pain. Eligible
14 patients are being invited to participate in the study by investigators at each study site. These
15 patients are being asked to complete an ePRO daily during the first week of treatment.
16 Observation is being discontinued if any of the following occurs: (1) death during observation,
17 (2) the patient's condition deteriorates and the healthcare professional determines that the
18 intervention cannot be continued; (3) the patient withdraws consent; and (4) the investigators

1 judge that observation cannot be continued for any other reason. As a rule, standard pain relief
 2 treatments are being provided at each facility. We are neither restricting the provision of
 3 combination or supportive treatment nor specifying the post-treatment.

4 **Box 1: Eligibility criteria**

Inclusion criteria	
1.	Patients diagnosed with remote metastasis or advanced recurrent cancer by a doctor.
2.	First treatment with strong opioid analgesics for cancer pain.
3.	Patients who are 20 years or older.
4.	Highest intensity of pain in the last 24 hours of an NRS score of 4 or higher.
5.	Patients providing written consent for participating in the study.
Exclusion criteria	
1.	Patients who have difficulty in providing ePRO data (e.g. those who do not have a smartphone or cannot use a tablet).
2.	Patients with cognitive impairments that would hinder PRO administration.
3.	Patients with mental illnesses that would hinder PRO administration.
4.	Patients whose main mechanism of pain is neuropathic.
5.	Other factors that the attending physician deems inappropriate.
ePRO, electronic version of the Patient-Reported Outcomes Questionnaire; NRS, numerical rating scale; PRO, Patient-Reported Outcomes Questionnaire	

5 **Outcome measures**

6 Table 1 shows the timeline of enrolment and assessment. We are using the JBQ-II [21] to assess

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 psychological barriers to opioid analgesic use and the Decision Regret Scale (DRS) [22] to
2 evaluate regret related to decision making. We are using the PRO version of the CTCAE [23]
3 and the CTCAE v5.0 to assess adverse events. We are evaluating pain severity using the Brief
4 Pain Inventory (BPI)-Short Form (SF) [24] and PPG. [25]

5

For peer review only

1
2
3
4 **Table 1: Study timeline**
5
6

Day	Visit 1	Time after initiating opioid therapy							Visit 2
	0 (baseline)	1	2	3	4	5	6	7	8–15
Patient reported outcomes :									
Psychosocial background	●								
JBQ-II	●							●	
PGIS								●	
DRS								●	
PRO-CTCAE	●							●	
BPI-SF (strongest pain in the last 24 hours)	●	●	●	●	●	●	●	●	
PPG	●								
Use of strong opioids before starting base medication with or without rescue medication (outpatients)		●							
Whether any dose of the base strong opioid was missed (outpatients)								●	
Clinician reported outcomes:									
Demographics and medical history	●								
CTCAE v5.0-JCOG	●								●
Presence of increased opioid dosage									●
Presence of opioid switching									●
Use of strong opioids before starting base medication with or without rescue medication (inpatients)									●

1
2
3
4 1 barriers. We are grading responses to the item ‘At present, how reluctant are you to use opioids
5
6
7 2 for pain relief?’ using the following seven-point scale: 0, not at all; 1, not reluctant; 2, almost
8
9
10 3 not reluctant; 3, neither; 4, slightly reluctant; 5, reluctant; and 6, extremely reluctant.

14 4 **Decision Regret Scale**

15
16
17
18 5 Regret is a negative emotion experienced when one realises or imagines that one has made the
19
20
21 6 wrong choice. It is a retrospective, unpleasant feeling, and people tend to focus on ‘what is good’
22
23
24 7 rather than ‘what is bad’. It has been reported to be associated with negative emotions, such as
25
26
27 8 disappointment, and involve some aspect of self-blame. [26] We are evaluating regret using the
28
29
30 9 DRS, which measures patient conflict regarding decision making during the treatment process.
31
32
33 10 [27] A Japanese version of the DRS has been developed and validated (Cronbach’s $\alpha = 0.85$).
34
35
36 11 [22] It consists of five items. The total score ranges from 0 to 100, with higher scores indicating
37
38
39 12 greater regret.

43 13 **Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse** 44 45 46 14 **Events**

47
48
49
50
51 15 The National Cancer Institute (NCI)-CTCAE is a standardised tool for assessing adverse events
52
53
54 16 during cancer treatment. However, since grading is based on the clinician’s judgement, it may
55
56
57 17 not be possible to accurately evaluate the patient's condition, especially when subjective aspects
58
59
60 18 are involved. [28] Basch et al. reported a discrepancy between clinicians’ and the patients’

1
2
3
4 1 assessments, indicating that clinicians underestimate CTCAE grades. [29] Therefore, the NCI
5
6
7 2 developed the PRO-CTCAE, which incorporates the concept of PRO into the CTCAE. [30] Its
8
9
10 3 Japanese version has been validated. [23] In this study, we are evaluating the participants' main
11
12
13 4 symptoms, such as pain, and characteristic adverse events related to opioid analgesic use, such
14
15
16 5 as nausea/vomiting, constipation, drowsiness, fatigue, and thirst. We are also evaluating an
17
18
19 6 additional item to measure the psychological burden of using opioid analgesics.

7 **Brief Pain Inventory-Short Form**

8 The effect of pain on daily life differs from pain intensity. It is related to the amount of pain
9
10 that hinders activities such as walking, bathing, and sleeping. The BPI is a standardised scale
11
12 that has been confirmed to be reliable and valid for assessing pain intensity and its effect on
13
14 daily life. [31] It is a 15-item questionnaire that evaluates pain. Each item is graded on an 11-
15
16 point scale, with scores ranging from 0 to 10. The Japanese version of this scale has already
17
18 been validated, and its reliability and usefulness have been established (Cronbach's $\alpha = 0.80$).
19
20 [24] To decrease the burden on patients related to the number of questions to be answered, we
21
22 are only using the 'worst pain in the last 24 hours' item of the BPI-SF, based on a report by
23
24 Atkinson et al.[32]

17 **Personalized Pain Goal**

18 The numerical rating scale (NRS) is generally used as an index of the average pain over 24

1 hours and the degree of pain-related disability in daily life (disturbance of life). It is an 11-point
2 scale, with scores ranging from 0 (none) to 10 (the worst possible). A score of ≥ 4 indicates
3 moderate pain/disability, while a score of ≥ 7 indicates severe pain/disability. [33] From the
4 perspective of personalized medicine for the treatment of cancer pain, it is important to involve
5 the patient in treatment goal setting and provide treatment with the aim of achieving those goals.
6 The PPG has recently been used as an outcome measure to determine pain-relief goals in non-
7 Japanese patients with cancer. [34] The PPG helps patients set a personalized pain-relief goal
8 using the following question: ‘At what level would you feel comfortable with pain? [25]’. In
9 our study, patients are being asked to use the NRS to indicate their pain treatment goals. Pain
10 treatment is considered to be successful (achievement of the PPG) if the patient's NRS score
11 for pain at the time of assessment is below the PPG.

12 **Others**

13 Since strong opioid use during the study period might affect the time to PPG achievement, the
14 following items are being investigated: (1) whether any dose of the base strong opioid was
15 missed, (2) presence of increased opioid dosage, (3) presence of opioid switching, and (4) use
16 of strong opioids before starting base medication with or without rescue medication.

17 **Sample size**

18 Since this is an observational study conducted to form a hypothesis rather than a confirmatory

1 study conducted to test it, [35] the sample size is focus on feasibility and is based on the number
2 of patients receiving strong opioid analgesics at the main medical institution. At Yokohama
3 City University Medical Center, 378 patients started receiving strong opioid analgesics in 2019
4 (total oral and injection, excluding local use). Among them, 60% met the eligibility criteria, and
5 60% of them were assumed to be able to express consent, which leads us to estimate that 136
6 people could enrol into this study within 1 year. In addition, it is expected that 10–40 patients
7 will be enrolled annually at Tokyo Medical University Hospital, National Cancer Centre
8 Hospital East, Yokohama-Minami Kyosai Hospital, and Kameda General Hospital. Based on
9 these estimates, we set the sample size target at 200.

10 **Data collection and timeline**

11 We are using the electronic data capture (EDC) systems Viedoc 4 and ViedocMe (Viedoc
12 Technologies, Sweden) and ePRO, to enrol the participants and collect their data. During
13 enrolment, the investigators input their personal accounts and passwords into the system.
14 Investigators at each site use the EDC system to input data into an electronic case report form.
15 Patients are being administered the PROs using an ePRO application on their device
16 (smartphone, tablet, or personal computer) at eight time points: at baseline and on days one to
17 seven. The patients may register their phone number or e-mail address in the EDC system and
18 use the ePRO reminder function. The investigators are providing the patients with details about

1
2
3
4 1 the trial. After obtaining patient consent, data regarding each patient's psychosocial
5
6
7 2 background; JBQ-II, PRO-CTCAE, and BPI-SF scores; and PPG are collected from their
8
9
10 3 electronic device. Data regarding demographics, medical history, and CTCAE v5.0-JCOG
11
12
13 4 score are collected, entered into the web-based EDC system at the study site, and linked to the
14
15
16 5 baseline PRO data. After starting to receive opioids, each patient is asked to record their BPI-
17
18
19 6 SF (worst pain in the last 24 hours) score daily for 7 days. On the last day, each patient is
20
21
22 7 administered the JBQ-II, PGIS, DRS, and PRO-CTCAE. Each patient's CTCAE v5.0-JCOG
23
24
25 8 data is collected by an investigator at the time of their next visit (days 8–15). In addition, we
26
27
28 9 are recording each patient's use of strong opioid medication prior to starting base medication
29
30
31 10 and whether any dose of the strong base opioid has been missed. The study timeline is presented
32
33
34 11 in Table 1.

12 **Data monitoring**

13 The data centre is located at the Department of Practical Pharmacy, School of Pharmacy, Tokyo
14 University of Pharmacy and Life Sciences, Tokyo, Japan. No personally identifiable
15 information is being entered into the EDC system, and the participating sites are not
16 communicating personal information to the data centre. Since this study involves data collection
17 using an EDC system, the data is stored on the server during the study period. After the end of
18 the study period, the data exported from the EDC system will be stored at the data centre until

1
2
3
4 1 presentation or publication. Following this, the data will be stored at the research secretariat
5
6
7 2 and data centre. Monitoring is being performed to ensure that the study is conducted according
8
9
10 3 to the protocol and that the data is collected accurately. Central monitoring is being performed
11
12
13 4 by the data centre based on the EDC data collected. The data centre has been submitting
14
15
16 5 monthly monitoring reports to the researchers, is sharing information with the researchers at all
17
18
19 6 the study sites, and is striving for improvement. There is no data monitoring committee, and
20
21
22 7 auditing has not been planned for this study.
23
24
25

26 8 **Harm**

27
28
29
30 9 This is a non-intervention observational study with low invasiveness. We expect no serious
31
32
33 10 harm to occur. However, the questionnaire contents may cause mental strain to the participants.
34
35
36 11 Consent may be withdrawn even while filling the questionnaire, and the study is explained in
37
38
39 12 detail to the participants prior to enrolment.
40
41
42

43 13 **Statistical analysis**

44
45
46
47 14 The primary outcome is the Japanese version of the Barriers Questionnaire-II (JBQ-II) score at
48
49
50 15 baseline. The secondary outcomes are the relationships between the total JBQ-II score and the
51
52
53 16 time to Personalized Pain Goal (PPG) achievement, JBQ-II scores at baseline and at the second
54
55
56 17 visit, changes in JBQ-II scores, and PPG achievement rate through Day 7. In addition, the
57
58
59 18 proportion of adverse events will be calculated using the Patient-Reported Outcomes (PRO)-
60

1
2
3
4 1 Common Terminology Criteria for Adverse Events (CTCAE) and CTCAE v5.0- Japan Clinical
5
6
7 2 Oncology Group (JCOG) for safety analysis. The mean JBQ-II score at baseline will be
8
9
10 3 calculated for all patients, and its 95% confidence interval will be estimated. The relationships
11
12
13 4 between the total JBQ-II score and the PPG achievement period, JBQ-II scores at baseline and
14
15
16 5 at the second visit, changes in JBQ-II scores, and PPG achievement rate through Day 7 will be
17
18
19 6 examined. Patients will be grouped based on their PGIS scores, and the difference between the
20
21
22 7 DRS score and PPG achievement rate between the two groups will be estimated and tested. The
23
24
25 8 relationship between the JBQ-II and trends in pain scores will be investigated. In addition, the
26
27
28 9 proportion of adverse events will be calculated using the PRO-CTCAE and CTCAE v5.0-JCOG
29
30
31 10 for safety analysis.

32 33 34 35 11 **ETHICS AND DISSEMINATION**

36 37 38 39 12 **Research ethical approval**

40
41
42
43 13 The study is being performed in accordance with the Declaration of Helsinki; Ethical
44
45
46 14 Guidelines for Medical and Health Research Involving Human Subjects published by the
47
48
49 15 Japanese Ministry of Education, Science and Technology and the Ministry of Health, Labour,
50
51
52 16 and Welfare; and the modified Act on the Protection of Personal Information. The protocol was
53
54
55 17 approved by the ethics committee (approval ID B200600091) of Yokohama City University on
56
57
58 18 24 August 2020. The protocol version was 1.1 in November 2020. The protocol has been
59
60

1
2
3
4 1 reviewed and approved by the institutional review board at the following study sites: Tokyo
5
6
7 2 Medical University Hospital, Yokohama Minami Kyousai Hospital, National Cancer Center
8
9
10 3 Hospital East, and Kameda General Hospital.
11
12
13

14 **Consent**

15
16
17
18 5 Before enrolment, an investigator explains the details of the study to the patients and gives them
19
20
21 6 time to think about it. All participants are informed of their right to withdraw their consent
22
23
24 7 without prejudice. The study will be conducted after obtaining written consent from all the
25
26
27 8 patients.
28
29
30

31 **Trial registration**

32
33
34
35
36 10 This trial has been registered at the University Hospital Medical Information Network Clinical
37
38
39 11 Trials Registry (UMIN000042443).
40
41
42

43 **Access to data**

44
45
46
47 13 Investigators can only access the case data collected at their respective study sites. Only clinical
48
49
50 14 data managers at the data centre have access to reported case data through the EDC system
51
52
53 15 during the study period.
54
55
56

57 **Dissemination policy**

58
59
60

1 The results of this study will be presented at conferences and published in national and
2 international peer-reviewed medical journals.

3 **DISCUSSION**

4 To date, most studies on psychological barriers to analgesia have not specifically studied the
5 use of strong opioid analgesics. The BAROC is an exploratory study investigating the
6 relationship between psychological barriers and improvement in pain. It is important to use
7 PROs, as pain improvement contributes to health-related quality of life. [36-39] Psychological
8 barriers may be influenced by opioid switching and analgesic use before the commencement of
9 regular strong opioid analgesics use. [18, 36, 40] These data are also being collected using the
10 EDC system.

11 The BAROC is the first multicentre study in Japan to evaluate the relationship between
12 psychological barriers and cancer pain. The study sites include university hospitals, specialised
13 cancer hospitals, and community hospitals, and it is expected that the enrolled patients will have
14 diverse demographics. One of the characteristics of this study is that eligibility is not limited by
15 performance status. This means that patients with a poor performance status may be eligible to
16 participate in this study. Patients on strong opioid analgesics often have a poor performance
17 status, and our data will reflect actual clinical practice.

1
2
3
4 1 Although the use of strong opioid analgesics can be beneficial in treating cancer pain, it can
5
6
7 2 also cause adverse events. Nausea and drowsiness commonly occur during opioid induction.
8
9
10 3 There is concern that these symptoms may lead to decreased adherence and, therefore,
11
12
13 4 interruption of pain treatment. In addition, the occurrence of adverse events can cause anxiety,
14
15
16 5 worry, and other psychological burdens, amplifying resistance to opioid analgesic use. In this
17
18
19 6 study, data on adverse event occurrence is being collected not only from physicians but also
20
21
22 7 from the patients themselves using the PRO-CTCAE. Because adverse events and
23
24
25 8 psychological barriers are closely related, precision in adverse event assessment is required.
26
27
28 9 Thus, it is important to use the PRO-CTCAE in addition to the CTCAE to consider the
29
30
31 10 relationship between psychological barriers and adverse events and enable high-quality adverse
32
33
34 11 event assessment.
35
36
37
38 12 Von Roenn et al. used case scenarios to survey 897 physicians from the Eastern Cooperative
39
40
41 13 Oncology Group about the prevalence of pain in cancer patients and physicians' perceptions of
42
43
44 14 managing pain. Although the case scenarios described patients with moderate to severe pain,
45
46
47 15 51% of physicians reported that they would prescribe 'weak' opioids. [41] However, for cancer
48
49
50 16 patients with moderate pain, low doses of morphine can result in a significantly greater
51
52
53 17 reduction in pain intensity than weaker opioids with similarly good tolerability and early effects.
54
55
56 18 [42] Therefore, it is important to remove barriers to introducing strong opioids at an early stage
57
58
59 19 and achieve rapid pain relief.
60

1
2
3
4 1 This study protocol has several limitations. First, this is an exploratory hypothesis-generating
5
6
7 2 observational study. The number of participants was not determined using statistical methods
8
9
10 3 and was based on the caseload of the participating institutions. Second, because this is an
11
12
13 4 observational study, we are neither specifying the explanation to be provided to the patients
14
15
16 5 before initiation of strong opioid analgesic use nor are we specifying the setting in which this
17
18
19 6 explanation is to be provided; each facility is following its protocol in this regard. Psychological
20
21
22 7 barriers may fluctuate depending on the method of explanation and the environment at that
23
24
25 8 time. There are situations in which treatment must be started despite significant barriers, as not
26
27
28 9 using opioid analgesics even when the pain becomes severe can significantly reduce quality of
29
30
31 10 life. This study was conducted in a population that has already started treatment. Therefore, the
32
33
34 11 results from this study cannot be applied to populations in whom strong opioid analgesics have
35
36
37 12 not yet been considered. Third, we exclude patients with cognitive impairment or mental illness
38
39
40 13 and those who cannot operate a smartphone or tablet from this study. Therefore, we will not be
41
42
43 14 able to enrol all patients receiving strong opioid analgesics. Most of the excluded participants
44
45
46 15 are likely to be older adults. Finally, due to the coronavirus disease-2019 pandemic, it may be
47
48
49 16 difficult to recruit patients due to restrictions on hospital functions and patients' reluctance to
50
51
52 17 receive care. As a result, enrolment for this study may need to be delayed.

53
54
55
56 18 The BAROC study may provide important information that may help reduce psychological
57
58
59 19 barriers to cancer pain relief in patients who are reluctant to use strong opioid analgesics.
60

1
2
3
4 1 Clarifying the relationship between the achievement of pain relief goals and psychological
5
6
7 2 barriers at the time of introduction of strong opioid analgesics will provide basic data for future
8
9
10 3 interventional studies, encourage education of healthcare providers for reducing psychological
11
12
13 4 barriers in advance to enable rapid pain amelioration, and contribute to improving the quality
14
15
16 5 of cancer pain treatment.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1 **Acknowledgements**

2 We are grateful to Mashiko T and Miyaji T for their long-term collaboration and advice. The
3 authors thank in advance all the patients, investigators, and institutions involved in this study.

4 We also thank Editage (www.editage.com) for providing writing support.

5 **Contributors**

6 TTs contributed to the study conception and is the principal investigator.

7 TTs, TF, TK, AK, and HHak participated in the design of the study.

8 TF, TK, and TY played a primary role in designing the data management approach.

9 TK and TY played a primary role in designing statistical analysis.

10 Data analysis and interpretation will be conducted by TTs, TF, TK, and TY.

11 TTs, RY, KK, AM, KA, TS, HM, TI, TM, HO, JK, TTa, HHam and YO have carried out
12 recruitment and collected the data.

13 All authors have read and approved the final manuscript and meet the criteria for authorship as
14 established by the International Committee of Medical Journals Editors.

15 **Funding**

16 This research received no specific grant from any funding agency in the public, commercial, or
17 not-for-profit sectors.

1
2
3
4 **1 Competing interests**
5
6
7

8 2 None declared.
9
10

11
12 **3 Patient consent for publication**
13
14

15
16 4 Not required.
17
18

19
20
21 **5 Provenance and peer review**
22
23

24
25 6 Not commissioned; externally peer-reviewed.
26
27

28
29 **7 Open access**
30
31

32
33 8 This is an open-access article distributed in accordance with the Creative Commons Attribution
34

35
36 9 Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt,
37

38
39 10 build upon this work non-commercially, and license their derivative works on different terms,
40

41
42 11 provided the original work is properly cited, appropriate credit is given, any changes made
43

44
45 12 indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.
46
47

48
49 **13 ORCID iD**
50
51

52
53 14 Takehiko Tsuno <https://orcid.org/0000-0002-5844-1226>
54

55
56
57 15 Tatsuhiro Fujimiya <https://orcid.org/0000-0001-8198-7465>
58
59
60

1
2
3
4 1 Takashi Kawaguchi <https://orcid.org/0000-0003-2446-7716>
5
6
7

8 2 **References**
9
10

- 11 3 1 Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF et al.
12 4 Global, regional, and national cancer incidence, mortality, years of life lost, years lived
13 5 with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A
14 6 systematic analysis for the global burden of disease study. *JAMA Oncol* 2018;4:1553–
15 7 68.
16 8 2 Horii M, Matsuda T, Shibata A, et al. Cancer incidence and incidence rates in Japan in
17 9 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer
18 10 Incidence in Japan (MCIJ) project. *Jpn J Clin Oncol* 2015;45:884–91.
19 11 3 Bruera E, Kim HN. Cancer pain. *JAMA* 2003;290:2476–9.
20 12 4 Morita T, Tsunoda J, Inoue S, et al. Contributing factors to physical symptoms in
21 13 terminally-ill cancer patients. *J Pain Symptom Manage* 1999;18(5):338-46.
22 14 5 Yamagishi A, Morita T, Miyashita M, et al. Pain intensity, quality of life, quality of
23 15 palliative care, and satisfaction in outpatients with metastatic or recurrent cancer: a
24 16 Japanese, nationwide, region-based, multicenter survey. *J Pain Symptom Manage*
25 17 2012;43:503–14.
26 18 6 Jacobsen R, Møldrup C, Christrup L, et al. Patient-related barriers to cancer pain
27 19 management: a systematic exploratory review. *Scand J Caring Sci* 2009;23:190–208.
28 20 7 Ward SE, Goldberg N, Miller-McCauley V, et al. Patient-related barriers to
29 21 management of cancer pain. *Pain* 1993;52:319–24.
30 22 8 Al-Atiyyat NMH, Vallerand AH. Patient-related attitudinal barriers to cancer pain
31 23 management among adult Jordanian patients. *Eur J Oncol Nurs* 2018;33:56–61.
32 24 9 Ell K, Sanchez K, Vourlekis B, et al. Depression, correlates of depression, and receipt
33 25 of depression care among low-income women with breast or gynecologic cancer. *J Clin*
34 26 *Oncol* 2005;23:3052–60.
35 27 10 Kwon JH. Overcoming barriers in cancer pain management. *J Clin Oncol*
36 28 2014;32:1727–33.
37 29 11 Nguyen LM, Rhondali W, De la Cruz M, et al. Frequency and predictors of patient
38 30 deviation from prescribed opioids and barriers to opioid pain management in patients
39 31 with advanced cancer. *J Pain Symptom Manage* 2013;45:506–16.
40 32 12 Chen CH, Tang ST, Chen CH. Meta-analysis of cultural differences in Western and
41 33 Asian patient-perceived barriers to managing cancer pain. *Palliat Med* 2012;26:206–21.
42 34 13 Berterame S, Erthal J, Thomas J, et al. Use of and barriers to access to opioid analgesics:
43 35 a worldwide, regional, and national study. *Lancet* 2016;387:1644–56.

- 1
2
3 1 14 Akiyama M, Takebayashi T, Morita T, et al. Knowledge, beliefs, and concerns about
4 2 opioids, palliative care, and homecare of advanced cancer patients: a nationwide survey
5 3 in Japan. *Support Care Cancer* 2012;20:923–31.
6 4
7 4 15 Morita T, Miyashita M, Shibagaki M, et al. Knowledge and beliefs about end-of-life
8 5 care and the effects of specialized palliative care: a population-based survey in Japan. *J*
9 6 *Pain Symptom Manage* 2006;31:306–16.
10 7 16 Gunnarsdottir S, Serlin RC, Ward S. Patient-related barriers to pain management: the
11 8 Icelandic Barriers Questionnaire II. *J Pain Symptom Manage* 2005;29:273–85.
12 9 17 Ward SE, Hernandez L. Patient-related barriers to management of cancer pain in Puerto
13 10 Rico. *Pain* 1994;58:233–38.
14 11 18 Gunnarsdottir S, Donovan HS, Serlin RC, et al. Patient-related barriers to pain
15 12 management: the Barriers Questionnaire II (BQ-II). *Pain* 2002;99:385–96.
16 13 19 Lin CC, Ward SE. Patient-related barriers to cancer pain management in Taiwan.
17 14 *Cancer Nurs* 1995;18:16–22.
18 15 20 Gunnarsdottir S, Sigurdardottir V, Kloke M, et al. A multicenter study of attitudinal
19 16 barriers to cancer pain management. *Support Care Cancer* 2017;25:3595–602.
20 17 21 Sakakibara N, Komatsu H, Takahashi M, et al. Validation of the Japanese version of the
21 18 barriers questionnaire II in cancer pain management: a cross-sectional study. *BMC*
22 19 *Palliat Care* 2020;19:102.
23 20 22 Tanno K, Bito S, Isobe Y, et al. Validation of a Japanese version of the decision regret
24 21 scale. *J Nurs Meas* 2016;24:E44–54.
25 22 23 Kawaguchi T, Azuma K, Sano M, et al. The Japanese version of the National Cancer
26 23 Institute’s patient-reported outcomes version of the common terminology criteria for
27 24 adverse events (PRO-CTCAE): psychometric validation and discordance between
28 25 clinician and patient assessments of adverse events. *J Patient Rep Outcomes* 2017;2:2.
29 26 24 Uki J, Mendoza T, Cleeland CS, et al. A brief cancer pain assessment tool in Japanese:
30 27 the utility of the Japanese Brief Pain Inventory--BPI-J. *J Pain Symptom Manage*
31 28 1998;16:364–73.
32 29 25 Tagami K, Kawaguchi T, Miura T, et al. The association between health-related quality
33 30 of life and achievement of personalized symptom goal. *Support Care Cancer*
34 31 2020;28:4737–43.
35 32 26 Zeelenberg M, Pieters R. A Theory of Regret Regulation 1.0. *J Con Psychol* 2007;17:3–
36 33 18.
37 34 27 Brehaut JC, O’Connor AM, Wood TJ, et al. Validation of a decision regret scale. *Med*
38 35 *Decis Making* 2003;23:281–92.
39 36 28 Basch E. The missing voice of patients in drug-safety reporting. *N Engl J Med*
40 37 2010;362:865–9.
41 38 29 Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting
42 39 using the National Cancer Institute Common Terminology Criteria for Adverse Events:

- 1 results of a questionnaire-based study. *Lancet Oncol* 2006;7:903–9.
- 2
- 3
- 4 1 Basch E, Dueck AC, Rogak LJ, et al. Feasibility of implementing the patient-reported
- 5 2 30 outcomes version of the common terminology criteria for adverse events in a
- 6 3
- 7 4 multicenter trial: NCCTG N1048. *J Clin Oncol* 2018;N1048:JCO2018788620.
- 8 4
- 9 5 31 Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann*
- 10 6
- 11 7 32 *Acad Med Singapore* 1994;23:129–38.
- 12 7
- 13 8 32 Atkinson TM, Mendoza TR, Sit L, et al. The Brief Pain Inventory and its ‘pain at its
- 14 8
- 15 9
- 16 9 32 worst in the last 24 hours’ item: clinical trial endpoint considerations. *Pain Med*
- 17 10 33
- 18 11
- 19 11 33 Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or
- 20 12 34
- 21 13
- 22 13 34 Dalal S, Hui D, Nguyen L, et al. Achievement of personalized pain goal in cancer
- 23 14
- 24 15 35
- 25 16
- 26 16 35 Vandembroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of
- 27 17
- 28 17 35 Observational Studies in Epidemiology (STROBE): explanation and elaboration.
- 29 18 36
- 30 19
- 31 19 36 Mercadante S, Adile C, Tirelli W, et al. Barriers and adherence to pain management in
- 32 20 37
- 33 21
- 34 21 37 Wang XS, Cleeland CS, Mendoza TR, et al. The effects of pain severity on health-
- 35 22 38
- 36 23
- 37 23 38 Park KU. Assessment of change of quality of life in terminally ill patients under cancer
- 38 24
- 39 25 39
- 40 26
- 41 26 39 Glaser AW, Fraser LK, Corner J, et al. Patient-reported outcomes of cancer survivors
- 42 27 40
- 43 28
- 44 28 40 Bağcıvan G, Tosun N, Kömürçü S, et al. Analysis of patient-related barriers in cancer
- 45 29 41
- 46 30
- 47 30 41 Von Roenn JH, Cleeland CS, Gonin R, et al. Physician attitudes and practice in cancer
- 48 31
- 49 31 41 pain management. A survey from the Eastern Cooperative Oncology Group. *Ann Intern*
- 50 32 42
- 51 33
- 52 33 42 Bandieri E, Romero M, Ripamonti CI, et al. Randomized trial of low-dose morphine
- 53 34
- 54
- 55
- 56
- 57
- 58
- 59
- 60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract Page 1 (b) Provide in the abstract an informative and balanced summary of what was done and what was found Page 3-5
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 6-8
Objectives	3	State specific objectives, including any prespecified hypotheses Page 8,9
Methods		
Study design	4	Present key elements of study design early in the paper Page 9,10
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 10,11
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Page 11 <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls N/A <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants N/A (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed N/A <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 11,12
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 13-17
Bias	9	Describe any efforts to address potential sources of bias N/A
Study size	10	Explain how the study size was arrived at Page 17,18
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why N/A
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding Page 13 (b) Describe any methods used to examine subgroups and interactions N/A (c) Explain how missing data were addressed N/A (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed N/A <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed N/A <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy N/A (e) Describe any sensitivity analyses N/A

Continued on next page

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed <input type="text" value="N/A"/> (b) Give reasons for non-participation at each stage <input type="text" value="N/A"/> (c) Consider use of a flow diagram <input type="text" value="N/A"/>
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders <input type="text" value="N/A"/> (b) Indicate number of participants with missing data for each variable of interest <input type="text" value="N/A"/> (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) <input type="text" value="N/A"/>
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <input type="text" value="N/A"/> <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <input type="text" value="N/A"/> <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures <input type="text" value="N/A"/>
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included <input type="text" value="N/A"/> (b) Report category boundaries when continuous variables were categorized <input type="text" value="N/A"/> (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period <input type="text" value="N/A"/>
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses <input type="text" value="N/A"/>
Discussion		
Key results	18	Summarise key results with reference to study objectives <input type="text" value="N/A"/>
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias <input type="text" value="Page 25"/>
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence <input type="text" value="N/A"/>
Generalisability	21	Discuss the generalisability (external validity) of the study results <input type="text" value="N/A"/>
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based <input type="text" value="Page 27"/>

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.